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 The importance of developing better cancer therapeutics cannot be over-emphasized. 
Among several approaches for improving patient outcome and satisfaction, targeted drug 
delivery has gained a lot of attention as a solution to maximizing therapeutic efficacy and 
minimizing the off-target side effects. Although there have been tremendous improvements in 
delivering chemotherapeutics using nanocarriers for achieving targeted drug delivery, reports 
on the use of this strategy for delivering therapeutic radionuclides are scarce. Considering the 
fact that radiation therapy is a standard of care for about half of all cancer patients, there is 
much evidence that more advancements are needed in the field of targeted delivery of 
therapeutic radionuclides. In this dissertation, with the goal of delivering targeted radiation to 
cancer, a neutron-activation approach was exploited for producing therapeutic radionuclides 
with minimum handling of highly radioactive substances. Various material matrices were 
explored for this strategy.  
 In Chapter 1, three different types of radiation therapy – external beam radiation 
therapy, internal radiation therapy and systemic radiation therapy – along with neutron-
activatable radionuclides and the rationale for proper isotope selection – were discussed. 
Additionally, carbon nanomaterials which have drawn great interest in numerous research 
fields for decades were thoroughly reviewed with a focus on biomedical applications in order 
to introduce the versatility of these materials. 
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 Among carbon-based matrices, graphene oxide nanoplatelets (GONs) and mesoporous 
carbon nanoparticles (MCNs) were chosen and examined for their application to systemic 
radiation therapy. In Chapter 2, GONs that were designed so that they would not leach neutron-
activated radionuclides in normal tissues but would selectively release their radioactive cargo 
in the tumor microenvironment are described. MCNs possessing a more uniform size and shape 
were investigated as a carrier for the stable isotope 165Ho are presented in Chapter 3. To achieve 
complete prevention of holmium leaching, the synthesis of holmium oxide in the pores of 
MCNs was employed, and this resulted in the MCNs maintaining their structural integrity with 
almost no holmium leaching after a prolonged neutron irradiation time (10 h). 
As an extension of this neutron-activation technology using radioactive needles that 
mimicked the microneedle technology adopted in transdermal drug delivery was developed for 
internal radiation therapy is described in Chapter 4. The ultimate goal of this work was to 
deliver high doses of targeted radiation directly into solid tumors by insertion of the radioactive 
needles. As a means to replace current radiation applicators used in the treatment of some solid 
tumors, custom-sized titanium and molybdenum needles were prepared as base materials. 
Neutron-activatable radionuclides (holmium and rhenium) were coated on the surface of these 
needles by pulsed laser deposition and chemical vapor deposition. The stability of the coatings 
under physiological-mimicking conditions as well as after neutron irradiation was extensively 
evaluated. 
 In summary, carbon-based nanocarriers and solid needles containing or coated with 
neutron-activatable elements were demonstrated to be very suitable for use in radiation therapy. 
Irradiation of these matrices in a neutron flux produced therapeutic amounts of radiation 
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CHAPTER 1 INTRODUCTION 
 
1.1 Radiation Therapy for Cancer 
 Radiation therapy is the method of destroying diseased cells with ionizing radiation, 
and it may be used for either treatment or palliative purposes [1]. With this therapy, cell death 
is induced primarily through either direct DNA strand breakage or indirect DNA damage 
caused by free radical generation [2]. Notably, cancer cells are more vulnerable to radiation 
than normal cells as they lack necessary mechanisms to recover from resulting damage in a 
timely manner [3]. Since the first cancer patient was treated with this therapy in 1896, there 
have been vast improvements in the field focusing on increasing radiation delivery to cancer 
cells while limiting damage to normal cells [4]. Recent advances have been achieved through 
the development of novel cancer imaging techniques. Image-guided radiation therapy, for 
example, has led to 50% decreased irradiation of normal tissue [1]. About 50% of cancer 
patients will receive radiation therapy alone, or in conjunction with surgery and/or 
chemotherapy, at some point during their treatment [3]. It is not only an effective and curative 
option but also favored from a cost perspective with reports indicating that radiation therapy 
accounts for only ~5% of the total cost of cancer care expenses. Currently, there are three 
different types of radiation therapy: external beam radiation therapy (EBRT), internal radiation 
therapy and systemic radiation therapy. These can be differentiated either by the location of the 
radiation source or the route of administration. Each type of radiation therapy will be discussed 
in the following sections.  
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1.1.1 External Beam Radiation Therapy (EBRT) 
 EBRT is the most prevalent type of radiation therapy [5]. As the name of EBRT 
suggests, this radiation therapy differs from other types in that the radiation source is outside 
of the body. High energy radiation in the form of X-rays, photons, protons or particles can be 
delivered to the tumor with this option [3]. Low-energy X-rays (kV range) and gamma rays 
were initial choices for EBRT but since the development of linear accelerators, their use has 
been mostly replaced by megavoltage X-rays [4].  
 Moreover, thanks to advancement in technology a number of new EBRT approaches 
have been introduced in the past few decades. Examples of these new options include: 3D 
conformal radiotherapy, intensity-modulated radiation therapy (IMRT), stereotactic 
radiotherapy, proton therapy and carbon ion therapy [4]. Among them, IMRT, has received a 
lot of attention in the field for its ability to deliver concentrated doses by adjusting radiation 
intensity with the assistance of computer-based inverse planning programs [6]. This method is 
currently used in many clinical settings for the treatment of head, neck, prostate and 
gynecological cancers [3].  
 The most pronounced side effect of EBRT is external skin damage, which may cause 
varying degrees of pain and discomfort for patients [7]. Unfortunately, this issue is inherently 
unavoidable owing to external placement of the radiation source. The problem is exacerbated 
by the delivery schedule which consists of with 20-30 fractions over 4-6 weeks because this 
dosing allows normal cells to recover from sub-lethal radiation damage [1, 8]. However, this 
frequent treatment schedule significantly lowers the patient compliance.  
 
1.1.2 Internal Radiation Therapy 
 Internal radiation therapy is commonly known as brachytherapy (brachy meaning 
‘short,’ in Greek) [9]. It is a compelling therapeutic option for selectively damaging cancer 
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cells by placing the radiation source, in the form of seeds, wires or pellets, within or adjacent 
to target tissues [10]. Since brachytherapy delivers the radiation dose inside of the body, it not 
only avoids the issue of skin damage but also delivers more radiation directly to target sites 
through a higher ratio of tumor to normal tissue dose, compared to EBRT [11, 12]. In the 
treatment of prostate cancer, for instance, the dose delivered by advanced EBRT (IMRT) is 
limited to ~80 Gy whereas the delivery more than 100 Gy can be achieved by utilizing 
brachytherapy [13]. 
 Radionuclides such as 226radium (Ra), 125iodine (I), 103palladium (Pa) and 192iridium (Ir) 
have been favored for brachytherapy applications [4]. They can be used via: external 
applicators (for external cancer sites), interstitial implantation (for temporary or permanent 
insertion into tissue), or intracavitary therapy (predominantly for cervical cancer) [14]. 
According to the International Commission of Radiation Units (ICRU), brachytherapy is 
classified as either low-dose-rate brachytherapy (LDR; 0.4-2 Gy/h) or high-dose-rate 
brachytherapy (HDR; higher than 12 Gy/h) based on delivery type [15]. 125I and 103Pd are 
common choices for LDR, and 192Ir is mostly used in HDR [16]. Depending on the size and 
location of cancer cells, the appropriate radionuclide, method of insertion, and dose may be 
selected to maximize patient outcomes.  
 There are a few distinct disadvantages to brachytherapy. Unlike EBRT, brachytherapy 
requires personnel handling (e.g., radiotherapist, nurses, radiation oncologists); these providers 
are unavoidably exposed to radiation at some point during the formulation preparation or 
treatment processes [9]. Additionally, this technique usually requires surgical insertion by 
skilled radiation oncologists [9, 17]. Lastly, only certain cancer sites can be treated due to 




1.1.3 Systemic Radiation Therapy 
 Systemic radiation therapy is an approach to delivering radiotherapeutics via oral 
ingestion, catheter infusion, or intravenous administration [19]. Common principles of drug 
delivery are applicable to this therapy, and the proper choice of both delivery method and active 
ingredient, in this case the radionuclides, is crucial in achieving desirable efficacy. Unlike 
brachytherapy, systemic radiation allows for radiopharmaceutical delivery to metastatic sites 
as well as primary tumor sites [20, 21].  
 Radionuclide emitting α-particles (e.g., 225actinium (Ac), 211astatine (At), 213bismuth 
(Bi)) and Auger electrons (e.g., 67gallium (Ga), 123I, 125I) have been actively investigated for 
use in systemic radiation therapy. However, translation to the clinic has been slow. A common 
limitation of α-emitters is their short therapeutic half-life; Auger-emitters, unfortunately, can 
only travel over extremely short distance (< 150 nm) [19]. Thus, β-emitters  (γ-photon emitters 
usually adopted in imaging application)  have been the dominant choice for systemic radiation 
applications [20, 22]. Among several candidates, 131I and 90yttrium (Y) have been preferred for 
systemic radiation therapy formulations due to high availability, inexpensive cost, and 
relatively long half-life (192.5 h for 131I and 64.1 h for 90Y) [19]. 
 As iodine is naturally taken up by the thyroid gland, radioactive iodine (RAI) has a long 
history of treating thyroid-related diseases. 131I was first used to treat a  patient with 
hyperthyroidism in 1941 and its first use in a thyroid cancer patient occurred in 1946 [20, 23]. 
A renowned example of RAI is 131I-metaiodobenzylguanidine (131I-mIBG). It is a compound 
with a structure very similar to norepinephrine that, when administered, accumulated in neural 
crest cells [24]. Accordingly, 131I-mIBG has been actively investigated as a therapeutic agent 
for neuroendocrine cancers (e.g., pheochromocytoma, neuroblastoma) [22, 24]. In spite of the 
active application of RAI, the relatively high energy-carrying γ-photons of 131I (364 keV) has 
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raised some safety concern as a γ-photon travels much further than β-particles and may induce 
off-target ablation [19, 25]. 
 On the other hand, 90Y is a pure β-emitter which does not have issues with γ-photon 
ablation and even delivers higher energy than 131I (Emax of 
90Y: 2.28 Me cf. Emax of 
131I: 0.61 
MeV) [26, 27]. The beneficial properties of yttrium have led to the development of several 90Y-
based formulations, a few of which have been introduced to the market. 90Y-containing glass 
microsphere was approved by the U.S. Food and Drug Administration (FDA) under the brand 
name TheraSphere®  for the treatment of hepatocellular carcinoma (HCC). Patients indicated 
for this drug are treated with the microparticles by catheter administration [27]. Furthermore, 
90Y has been conjugated to a monoclonal antibody (ibritumomab) and the resulting 
radioimmunotherapy agent, Zevalin® , was approved by FDA for the treatment of non-
Hodgkin’s lymphoma [28].  
 
1.1.4 Neutron-Activatable Radionuclides 
 Neutron-activation is a process of generating radioactive substances by conferring 
neutrons to stable nuclei. The process can be incorporated into brachytherapy and systemic 
radiation therapy as well as utilized by nuclear medicine imaging applications [29]. When 
stable isotopes capture additional neutrons, they become heavier (excited) and decay by 
emitting particles (α or β) and/or γ-photons. The amount of radioactivity generated by neutron 
irradiation can be calculated by the following equation: 
𝐴 = 𝑛 ∗ 𝑓 ∗ 𝜎 ∗ (1 − 𝑒−𝜆𝑇) ∗ 𝑒−𝜆𝑇  
where A is radioactivity (Ci), n is the number of atom (multiplied by natural abundance factor), 
f is neutron flux density (neutrons cm-2 s), σ is neutron cross-section (cm2), λ is decay constant 
(ln2/t1/2, h




 There are a number of factors involved in generating radioactivity by neutron-
activation. Some parameters, such as natural abundance, neutron cross-section and half-life, 
are intrinsic proprieties of the radionuclides themselves and cannot be altered during the 
activation process. Thus, neutron-activatable radionuclides need to be wisely selected for 
appropriate therapy and imaging purposes. In addition to element selection, there are still two 
aspects that must be considered when manipulating this process: irradiation time and neutron 
flux. Considering that the neutron flux is often limited by type of nuclear reactor and its set-
up, adjusting the neutron irradiation time is regarded as a more realistic option for controlling 
final radioactivity.  
 
Candidates for Neutron-Activatable Radionuclides  
 To examine potential neutron-activatable radionuclides, a list of clinically translated or 
investigated radionuclides are presented in Table 1.1. An important factor in selecting a 
suitable candidate for this application is its natural abundance. In the case of samarium (Sm), 
4 out of 7 isotopes can generate sufficient amounts of radioactivity following neutron-
activation. Since they all have different half-lives and energy levels, the use of Sm for neutron-
activatable formulation requires purification processes in order to avoid complicated dosimetry 
calculation. Thus, with respect to natural abundance, 100% natural abundant elements such as 
Y, Au, and Holmium (Ho) are more desirable than other elements that exist as other isotopes. 
As shown in the above equation, neutron cross-section – probability of reaction between 
neutron and nucleus – is directly proportional to the production of radioactivity [30]. For 
example, clinically translated Y has relatively low neutron cross-section (1.28 barn) which is 
77-fold lower than Au and 46-fold lower than Ho. Based on this knowledge, Y cannot yield 
the same radioactivity that may be achieved by Au or Ho under the same irradiation conditions. 
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Half-life, another important factor in dose calculations, must also be taken into consideration 
for neutron-activation. Since elements that produce isotopes with longer half-lives are 
disadvantageous in generating a large amount of radioactivity, it is not surprising that in a 
simulation of neutron irradiation, Au could not produce more radioactivity than Ho despite its 
~1.7-fold higher neutron cross-section (Table 1.1). Thus, Ho was selected as the optimal 
investigative agent for the current research.  
 
1.2 Carbon Nanomaterials in Biomedical Applications 
 In the biomedical field, tremendous developments, innovations and improvements are 
continually emerging, and reports of new findings are being published nearly every day. For 
the past decade, many developments have been accompanied by significant advances in 
nanotechnology which, in turn, have created new opportunities for tackling many long-
harbored challenges. For example, advances in nanotechnology have allowed for the 
development of nanoparticle-based drug delivery systems which offer distinct advantages over 
conventional therapeutics, including: better tumor accumulation through exploitation of 
passive and active targeting, more favorable pharmacokinetics, and controlled or sustained 
drug release [32]. In order to exploit the unique benefits of this type of formulation, various 
kinds of nanomaterials including lipids, polymers, viruses, and inorganic composites (e.g., 
gold, silica, iron oxide, quantum dot) have been explored as vehicles for cargo delivery [33-
39]. Among them, carbon nanomaterials such as carbon nanotubes (CNTs), fullerenes and 
graphene oxide nanoplatelets (GONs) have been actively investigated substances. Research 
into fullerene and graphene, in particular, has yielded Nobel Prize Winning research in the 
fields of Chemistry (1996) and Physics (2010), respectively [40, 41].  
 Carbon nanomaterials have garnered interest in a number of areas including electronics, 
biosensors, energy storage, mechanical systems, and biomedical application [42]. Due to 
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variations in size and shape of these materials, each carbon nanocarrier possesses distinct 
characteristics, but all carbon nanomaterials share the unique properties of chemical inertness, 
mechanical strength, semi-conductive behavior, superior thermal conductivity, elasticity, large 
surface area and biocompatibility[42, 43]. A notable drawback of carbon nanomaterials, 
however, is their insolubility in aqueous solvents. To overcome this issue, surface 
functionalization strategies have been examined; these will be discussed in subsequent 
sections. While fullerenes have the longest history of carbon nanomaterial research , starting 
from their 1985 discovery, CNTs are arguably the most heavily investigated material among 
the carbon family [44]. In this regard, most carbon nanomaterial studies have been conducted 
using CNTs; the approach refined in these studies has subsequently been used in research 
utilizing fullerenes and GONs. 
 Three of the most extensively investigated carbon nanomaterials are CNTs, fullerenes, 
and GONs and can be applied for imaging and therapeutic purposes. Along with these agents, 
mesoporous carbon nanoparticles (MCNs) have arisen as a relatively new class of carbon 
nanomaterials that is reported to have an exceptionally large surface area (up to 3000 m2 g-1) 
in addition to tunable size and porosity [45, 46]. Since research in this area is still in its 
nascence, most available publications have focused on other applications (e.g., energy storage) 
and reports of utilizing MCNs for therapeutic applications are not yet common [47]. 
 
1.2.1 Background and Synthesis 
Carbon Nanotubes 
 CNTs are hollow and cylindrical structures with a high aspect ratio and are formed from 
a rolled graphitic layer. Based on the number of graphene layers, CNTs are largely classified 
as single-wall nanotubes (SWNTs) or multi-wall nanotubes (MWNTs). The diameter of 
SWNTs is typically 1-2 nm while that of MWNTs is in the range of 2-25 nm. The length of 
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both SWNTs and MWNTs can range from hundreds of nanometers to a few micrometers [48]. 
CNTs are small but remarkably strong (in terms of high Young’s modulus and high tensile 
strength), especially when considering their low density. For instance, the density-normalized 
modulus of CNTs is approximately 19- and 2.4-fold higher than that of steel or silicon carbide 
nanorods, respectively [49]. CNTs were initially synthesized by electronic-arc discharge 
method from graphite with the assistance of metal catalysts [50]. Other synthesis methods (e.g., 
laser ablation technique, chemical vapor deposition (CVD), electrolysis, heat treatment of 
polymer) were investigated to attain a higher yield, narrower size distribution and efficient 
scale-up [51, 52].  
 
Fullerenes 
 Fullerenes, like graphite and diamonds, are a type of carbon allotrope. The first 
discovered fullerene was C60, a spherical and hollow carbon cage measuring approximately 1 
nm in size [44, 53]. Soon after this finding, various sizes of fullerenes were synthesized and 
further distinguished as lower fullerenes (< C60; e.g., C28, C36) or higher fullerenes (> C60; e.g., 
C80, C94) [54-56]. Though fullerenes were found to exist in nature, they have been detected in 
meteors and in space, they have been generally synthesized by the arc-discharge method – a 
process involving evaporating graphite electrodes and recondensing them in a helium 
atmosphere [57-60]. Based on the modification methods, this type of carbon allotrope can be 
further classified as endohedral fullerenes (loading other molecules inside of their structure) 
and exohedral fullerenes (attaching other molecules outside of carbon skeleton) [59].  
 
Graphene Oxide Nanoplatelets 
 Graphite consists of several stacked layers and one single layer of this structure is called 
a graphene. Graphene was previously regarded to be a theoretical material until its isolation in 
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2004 by the mechanical exfoliation of graphite [59]. The first experimental separation of 
graphene was performed by the labor-intensive scotch tape method (repetitive peeling until a 
single layer is isolated) [61]. In 2006, chemical exfoliation was developed. The process 
involves oxidizing graphite in water and adding mechanical energy (sonication) [62]. The 
oxidized form of graphene is called graphene oxide (GO) and is the preferred form for 
biomedical application because of its ability to dispersion both aqueous and organic solvents. 
Conversely, GO loses its electrical conductivity during the oxidation process which raises a 
problem in its use for other applications. Fortunately, this conductivity can be recovered by 
chemical or thermal reduction processes which GO to reduced graphene oxide (RGO) [63]. 
Alternative methods have been proposed for graphene preparation (e.g., CVD, epitaxial growth 
from silicon carbide, un-zipping CNTs), yet the chemical approach is still preferred due to its 
low-cost, scalability, and relatively ease in processing [63, 64].  
GO is a single-atom-thick 2-dimensional structure – thickness is typically measured to 
~ 1 nm by atomic force microscopy (AFM) – but lateral dimensions are variable [65]. Synthesis 
of nano-sized graphene oxide, referred to as graphene oxide nanoplatelets (GONs), can be 
achieved using strong mechanical energy to break GONs down to a nano-scale. GONs have 
been extensively explored for a number of different biomedical applications [66]. 
 
Mesoporous Carbon Nanoparticles 
 Thanks to large surface area, porous materials are widely utilized as adsorbents for 
pollutant removal (e.g., heavy metals) [67]. Depending on the pore size, they are subdivided to 
microporous (< 2 nm), mesoporous (2-50 nm) or microporous (> 59 nm) [68]. Since 
mesoporous silica nanoparticles (MSNs) have emerged as a new class of drug carrier, the 
attention has shifted to similarly structured carbon materials: MCNs [37, 69]. MCNs possess 
advantages over other carbon nanomaterials, in terms of structural rigidity and low density, and 
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over MSNs, due to a larger surface area for cargo loading. Moreover, MCNs have been shown 
to have better biocompatibility profile compared to MSNs [70]. MCNs are typically 
synthesized by either the hard-template or soft-template method. The hard-template strategy 
uses MSNs as a template, which are removed by acid treatment (hydrofluoric acid) when 
porous carbon structure is formed [71]. In the case of the soft-template method, self-assembly 
polymers (e.g., Pluronic®  F-127) are employed as a template, which can later be eliminated by 
thermal treatments that degrade the polymeric template but allow carbon nanoparticles to stay 
intact at high temperatures (700-900 °C) in the presence of inert gas [46]. The latter method is 
favorable owing to lower production costs (avoiding the use of expensive MSNs) and higher 




 In an attempt to improve carbon nanoparticle dispersibility in aqueous solvents, several 
different surface modification strategies have been reported. These strategies can be classified 
as either covalent or non-covalent modification methods. Covalent modification involves 
introducing functional moieties on existing nanomaterials. The most common strategy for 
covalent modification has been introducing carboxylic group (-COOH) by oxidation. Since 
very strong acids, such as hydrochloric acid, nitric acid and sulfuric acid, are typically used for 
this oxidation, excessive washing processes must be followed [72-75].  
This acid treatment is actually a part of typical GONs synthesis to attach carboxylic 
acid, hydroxide, and epoxide on the GON surface, hence reactions of adding functional groups 
are not prerequisite for GONs [65]. Many other functional groups (e.g., amine, ester, thiol) can 
also be formed on the surface of these carbon nanomaterials via assorted chemical reactions 
[76-78]. Upon introduction of various functional groups, a number of different conjugation 
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strategies can be conducted, including a well-known amine coupling reaction through EDC [1-
ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride] and NHS [N-
hydroxysuccinimide] [78, 79]. Through the agency of conjugation, several chemical or 
biological entities can be attached to carbon nanomaterials to act as dispersing agents [80-82].  
 
Non-Covalent Modification 
 On the other hand, the non-covalent modification does not require functional group 
induction on the surface of carbon nanomaterials. Rather, this approach exploits hydrophobic-
hydrophobic, van der Walls, and electrostatic interactions between carbon structures and 
adducts [56, 78, 83]. If the adduct carries aromatic groups in its chemical structure, stronger 
interaction – ᴨ-ᴨ stacking – can be formed with aromatic regions of carbon nanomaterials [50]. 
Amphiphilic surfactants and polymers, which can bind to hydrophobic carbon nanomaterials 
in order to confer dispersibility in aqueous solvents, have been popular choices as non-covalent 
modification agents; other biological molecules (e.g., proteins, nucleic acids, carbohydrates) 
have also been widely studied for this strategy [78, 83]. A number of studies detailing the 
attachment of non-covalent adducts have been conducted with CNTs and GONs, but research 
on fullerenes using this approach remains relatively scarce. Interestingly, fullerenes have been 
investigated as guest molecules for encapsulation within other carriers (e.g., cyclodextrins, 
micelles, liposomes), likely due to their small size (~1 nm) and therapeutic capabilities as both 
antivirals and antioxidants [77]. As few studies have investigated MCNs for biomedical 
application, it is difficult to find literature detailing experimental methods for this type of 
application. However, considering that MCNs are capable of moiety-loading via non-covalent 




Covalent Modification vs. Non-Covalent Modification 
 There is no perfect strategy for surface modification. Each method has its benefits and 
its drawbacks. The main advantage to the covalent method is the ability to offer higher 
dispersion stability in organic or aqueous solvents due to the stronger covalent linkage between 
functional groups of carbon nanomaterials and the dispersing agents [42]. However, the 
structural rigidity of carbon nanomaterials is easily weakened and can be broken down during 
acid treatment or other functional group introduction processes [50]. Non-covalent 
modification has been favored as a means of a simple, quick, and non-destructive method of 
surface modification [86]. Regarding the lower dispersion stability of this method compared to 
covalent conjugation, Liu et al. have claimed that a carefully and rationally chosen amphiphilic 
moiety (e.g., phospholipid polyethylene glycol) could provide an excellent stability in the 
biological environment [87].  
 
1.2.3 Cellular Uptake and Toxicity  
Cellular Uptake  
 Among CNTs’ many superior properties, its ability to easily cross cell membranes has 
made them an attractive carrier for therapeutic and imaging modality delivery application [80, 
88]. Previous publications have suggested that functionalized CNTs (f-CNTs) are internalized 
in cells via both passive and endocytosis-independent methods by the aid of their needle-like 
structure; others have insisted that there were different cell uptake mechanisms heavily 
dependent on the size and functionalization strategies of CNTs [80, 88, 89]. These patterns 
were observed with other functionalized carbon nanomaterials as well [85, 90, 91]. Based on 
these findings, a variety of cargos (e.g., drug molecules, genes, vaccines, peptides, proteins) 
can be delivered to the intracellular target sites with the assistance of carbon nanocarriers [66, 




 Toxicity of carbon nanomaterials is another important subject. With respect to CNTs, 
their significant toxicity hampers their translation into the clinical setting [93]. A study 
conducted by Poland et al. found that CNTs induced asbestos-like pathogenicity stemming 
from the structural similarity with said toxin (i.e. needle-like fibrous shape) [94]. There have 
been countless debates regarding the toxicity of CNTs [95, 96]. Numerous publications have 
expressed concerns regarding the toxicity of CNTs, specifically with respect to 
unfunctionalized CNTs which can aggregate and induce necrosis, apoptosis and inflammation 
in both in vitro and in vivo models [89, 93]. Thus, well-dispersed CNTs with proper 
functionalization have been shown to successfully prevent signs of toxicity and have 
immensely enhanced their safety profile [89]. Since many synthetic methods utilize metal 
catalysts (e.g., iron, cobalt, nickel), toxicity assessments must be evaluated following the 
successful removal of the metal catalysis [51, 93]. Overall, the prevention of CNTs toxicity can 
be managed by a number of factors, including alterations in structure, size, aspect ratio, surface 
modification strategies and synthetic method [93, 97] 
 Early toxicity studies with fullerenes have identified concerns about oxidative stress 
[98, 99]. Later studies, however, determined that proper removal of organic solvent 
(tetrahydrofuran) and subsequent functionalization was able to prevent this issue [100, 101]. 
According to Sayes et al., surface modification of fullerenes rendered its lethal dose by up to 7 
orders of magnitude [102]. As graphene has become a rising star among carbon nanomaterials 
over the past decade, subsequent toxicity assessments have found that results were no different 
compared to other members of the carbon family. Though pristine graphene has been shown to 
induce cytotoxicity through the generation of reactive oxygen species (ROS), GONs and rGO 
nanoplatelets (rGONs) exhibit enhanced biocompatibility [103]. Additional linking 
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biocompatible moieties such as polyethylene glycol (PEG) and dextran to GONs has been 
found to improve safety profiles [66]. Yang et al. investigated the long-term toxicity of 
PEGylated GONs and concluded that there was no observable toxicity even at high doses (20 
mg/kg) over a 3 months follow-up period [104].  
 In the case of MCNs, there are a limited number publications available for evaluating 
the toxicity of these relatively new members of the carbon family. Despite the fact that pristine 
MCNs prepared by hard-template and soft-template methods did not present cytotoxicity up to 
10 and 50 µg/mL, respectively, higher concentration clearly exhibited undesirable cytotoxic 
effect [46, 85]. To increase the dispersity of MCNs, Zhu et al. introduced carboxyl groups on 
the surface of MCNs and did not observe any cytotoxicity at testing concentrations (0.23 to 23 
µg/mL) [74]. However, the concentration range tested in this study was lower than previous 
reports with pristine MCNs. Xu et al. functionalized MCNs with polyethylenimine (PEI) and 
folic acid (FA), and confirmed that this formulation does not exhibit toxicity within the range 
of 10-75 µg/mL [105]. This study did not disclose the percent composition of MCNs out of 
FA/PEI/MCNs; thus, it is difficult to conclude improved toxicity with this functionalization 
strategy. Based on toxicity examinations of previous carbon nanomaterials, a properly designed 
study with well-assorted functionalization of MCNs is anticipated to demonstrate superior 




 Numerous researchers have been intrigued in optical properties of carbon 
nanomaterials. Exploiting the intrinsic characteristics of carbon structure for imaging 
applications is an advantageous method for long-term tracking, particularly when compared 
with fluorescence or radionuclide-labeling methods where trackers may be slowly detached or 
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completely decayed over time [106]. Since the biological system is substantially transparent 
and exhibits low autofluorescence in the near-infrared (NIR) region, strong NIR absorbance of 
CNTs from small band gaps allows them to be utilized in photoluminescence imaging, even 
without attaching a fluorophore to the carrier [87, 88]. A large band gap between excitation 
(550 – 850 nm) and emission (900 – 1600 nm) of CNTs is also beneficial because it can be 
easily distinguished from the background [87]. Using this imaging technique, Welsher et al. 
successfully visualized CNTs in vivo and employed them for intravital microscopy [107]. Low 
photoluminescence quantum efficiency of CNTs (less than 0.01) has been a limiting factor for 
this imaging option, but it has been suggested that this method could be enhanced by the 
appropriate surface coating methods or the addition of photoluminescence enhancers (e.g., gold 
nanoparticles, quantum dots) [42]. 
 In addition to CNTs, GONs have been actively studied as a means for fluorescence 
imaging. When graphene or GO is generally smaller than 10 nm, they are referred to as 
graphene quantum dots (GQDs) and their intrinsic fluorescence can be visualized over a broad 
range (from ultraviolet to NIR) [108]. An interesting phenomenon is that large-sized pristine 
graphene is not an inherently fluorescent material but does emit fluorescence due to quantum 
confinement and edge effects following the induction of functional groups with size reduction 
[109]. Several merits – including the capability for color tuning and quantum yields up to 28% 
– are additional benefits when they are functionalized [64]. By using GQD’s versatility in 
fluorescence imaging, Wu et al. showed that they can be displayed with different colors (blue, 
green and red) and be visualized in vivo [110]. 
 Adequate quantum yields continued to be an issue with respect to fullerenes (less than 
0.1%). To overcome this issue, Lin et al. attempted to break the structural symmetry of C60. 
Results of this method suggested that the quantum yields were boosted 2-3-fold with this 
functionalization method [111, 112]. Nevertheless, this fluorescence imaging technique is not 
17 
preferred for fullerenes because of its low practicality (fluorescence emission in the visible 
region) [108]. While there are some publications concerning the incorporation of fluorescence 
molecules to MCNs, studies utilizing MCNs’ intrinsic fluorescence have not been conducted 
yet [85, 113]. 
 
Raman Imaging 
 Raman spectral imaging is a relatively new technique which can offer useful 
information about the activity of carbon nanoparticles at the in vitro, in vivo, and even at the 
molecular-level [114]. The strong intrinsic resonance of Raman scattering at the graphitic-band 
(G-band; high frequency; 1500 – 1600 cm-1) of carbon nanomaterials originates from the 
unique sp2 chemical structure; this property allows them to be investigated as Raman imaging 
agents [87, 115]. Though GONs could be imaged with this technique in vivo, most 
investigations of Raman imaging applications were performed with CNTs [116, 117]. 
 The radical breathing mode (RBM; low frequency; 100 – 300 cm-1) has been observed 
only in CNTs. Along with G-band, this method is most effective in distinguishing CNTs from 
background spectra and is the most commonly adopted imaging method [118]. Attaching 
multicolor Raman contrast agents to CNTs confers a multiplexing capability, providing the 
possibility for imaging several biological incidents simultaneously in vivo [114]. As previously 
discussed, exploiting the intrinsic characteristics of CNTs in Raman imaging allows and 
extended visualization period compared to other modalities. Thus, using this technique, a study 
by Liu et al. was able to track the biodistribution and excretion of CNTs in vivo over a 3 month 
follow-up period [106]. Nonetheless, the general issue with Raman imaging is a severely low 
scattering cross section which is much smaller than that of fluorescence [115]. To overcome 
this problem, various strategies have been suggested to enhance Raman scattering, including 
the addition of nano-sized metal nanoparticles on CNTs. This method remains the preferred 
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solution for overcoming the limitations of Raman imaging [114]. For example, Kneipp et al. 
found that CNTs with silver colloidal clusters could augment Raman scattering up to 12 orders 
of magnitude [119].  
 
Photoacoustic imaging 
 Photoacoustic imaging is a hybrid technique that incorporates optical and ultrasound 
imaging by applying the photoacoustic effect [120]. Photonic energy – usually generated by a 
short laser pulse – induces heating and acoustic (ultrasonic) emission in soft tissues by 
generating molecular vibrations in response to thermal expansion. These emissions can be 
detected by an ultrasound receiver and mapped into an image [121]. Due to higher spatial 
resolution and deeper tissue imaging capabilities compared to other optical imaging methods, 
this modality has been favored by researchers over the past decade [122]. Considering that 
scattering in deep tissue imaging can greatly lower spatial resolution, weaker ultrasound 
scattering with photoacoustic imaging, than optical scattering, is a valuable advantage [123]. 
In contrast to ultrasound imaging, photoacoustic imaging can also provide better specificity; it 
can even detect trace hemoglobin, lipids and other light-absorbing substances [120]. However, 
contrast agents are necessary for photoacoustic imaging. Carbon nanomaterials, such as CNTs, 
can be used as exogenous contrast agents for this application by virtue of their marked 
photoacoustic signal production from high optical density in the visible and NIR regions [108, 
124].  
 As CNTs are easily modifiable for the attachment of targeting or signal-enhancing 
moieties, in addition to its intrinsic photoacoustic property, these materials have been identified 
as attractive agents for this imaging system [125]. De La Zerda et al. demonstrated that CNTs 
conjugated with cyclic Arg-Gly-Asp (RGD) peptides led to approximately 8-fold stronger 
photoacoustic signals in tumor imaging when compared to pristine CNTs [122]. The system 
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was even further enhanced by adding an indoyanine green (ICG) dye to the CNTs, resulting in 
~300-fold better signal in vivo with sub-nanomolar sensitivities [126]. Other plasmonic 
nanoparticles (e.g., gold, silver) have also been frequently complexed with CNTs to boost 
photoacoustic signal and sensitivity because of their surface plasmon resonance effect [125]. 
Functionalized fullerenes, too, can be utilized with this imaging modality to offer high contrast 
images. Krishna et al. produced water-soluble fullerenes by the introduction of hydroxyl groups 
and used them for in vivo photoacoustic imaging [127]. Among graphene-based materials, 
rGONs are favored over GONs for photoacoustic images because of their intact pi-conjugated 
structure [108]. Sheng et al. showed that rGONs generated about 3-fold higher photoacoustic 
signals compared to GONs when employed for in vivo photoacoustic imaging [128].  
 
Magnetic Resonance Imaging (MRI) 
 Though there have been tremendous improvements in the aforementioned optical 
imaging techniques, the most prominent limitation of these is their poor tissue penetration issue 
which limits their applicability to human subjects. Accordingly, conventional radiological 
imaging modalities are still preferred in terms of translation to practice. MRI is one of the most 
widely used techniques for non-invasive medical imaging in the current clinical setting. Like 
photoacoustic imaging, the use of contrast agents is necessary for this imaging method. To 
enhance the sensitivity of MRI, the majority of research has utilized either gadolinium (Gd)-
based T1 or iron oxide-based T2 contrast agents; some of these studies have also integrated 
these agents with carbon nanomaterials [66, 77, 129].  
 Gd-based contrast agents (GBCAs) currently dominate the MRI contrast agent market 
due to their superior paramagnetic properties. Thus, most has approached MRI imaging by 
chelating Gd on CNTs [130, 131]. Sitharaman et al. incorporated Gd on CNTs and reported 
that they could achieve 40 to 90-fold larger reflexivity than currently approved MRI contrast 
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agents by allowing facile access for hydrogen of water to Gd [132]. This approach is certainly 
applicable to GONs. In fact, Gizzatov et al. coordinated Gd ions to carboxyl groups on GONs 
and reported much higher reflexivity values compared to the commercial product, Magnevist®  
[133]. On the other hand, the issue of nephrogenic toxicity is a highly studied complication of 
GBCAs which is caused by Gd-leaching from the chelating matrix [134]. To avoid this 
problem, others researchers selected iron oxide as an MRI contrast agent. Using iron oxide-
based contrast agents, Ananta et al. showed that even negligible iron (Fe) content (less than 1 
w/w%) on CNTs induced remarkably efficient T2 relaxation [135]. Applying this idea to GONs, 
Ma et al. prepared iron oxide-loaded GONs and demonstrated successful in vivo MRI imaging 
[136]. 
 The closed carbon cage structure of fullerenes allows Gd encapsulation instead of 
chelation at the surface of the carbon allotrope. When a metal ion is located inside the fullerene 
cage the complex is referred to as a ‘metallofullerene,’ a complex which has been actively 
researched for fullerene applications. It was conceived as an effective system of keeping 
potentially toxic metal ions within the rigid carbon cage, preventing unwanted release of Gd 
ions from Gd-related toxicity [100, 137]. Using Gd-encapsulated fullerenes, Mikawa et al. 
showed 20-fold enhanced proton relativity compared to the marketed agent (Magnevist® ) 
[138]. Dorn’s group later developed a method of encapsulating three metal atoms per fullerene 
by selecting larger fullerenes (C80) for metal loading instead of the typical agents (C60). Using 
this approach, they further improved relativity up to 40-fold compared to a commercial MRI 
contrast agent (gadodiamide) [139, 140].   
 
Nuclear Medicine Imaging  
 In addition to radiolabeling, carbon nanomaterials have displayed their potential for 
nuclear medicine imaging applications such as single photon emission computed tomography 
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(SPECT) and positron emission tomography (PET). Prior to radionuclide attachment, chelators 
are usually conjugated to carbon nanomaterials in order to ensure binding between carbon 
structure and radionuclides. Commonly adopted chelators in nuclear medicine imaging 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-
1,4,7-triacetic acid (NOTA) and diethylenetriaminepentaacetic acid (DTPA) [141, 142]. 
Imaging agents such as 86Y and 64copper (64Cu) bound to CNTs via DOTA have successfully 
exhibited in vivo PET imaging [141, 143]. Wu et al. linked DTPA to CNTs via the covalent 
method and chelated the adduct with a frequently consumed radionuclide, 99m technetium 
(99mTc) for SPECT imaging [144]. Exploiting the unique structural characteristics of CNTs, 
Hong et al. trapped radionuclides with metal halides (Na125I) inside of CNTs and used them for 
in vivo SPECT imaging [145]. While radiolabeled peptides or proteins are capable of chelating 
only a few radionuclides per biomolecule, nanocarriers are able to carry a large number of 
chelators. For example, previous studies have successfully coupled 114 chelators of 111indium 
(111In) per CNT [48].  
 By an analogous system, Hong et al. conjugated NOTA on GONs for the chelation of 
two radionuclides, 64Cu and 66Ga, as a method for in vivo PET imaging to visualize tumor 
vasculature [146, 147]. Furthermore, Cornelissen et al. attached DTPA on GONs via ᴨ-ᴨ 
stacking and labeled 111In for in vivo SPECT imaging [148]. While research by Li et al. attached 
a chelator outside of fullerenes for in vivo PET imaging (with 64Cu labeling), it is anticipated 
that future endeavors will use metallofullerenes for repeat experiments [149]. Radionuclides 
such as 166Ho, 177lutetium (177Lu) and 99mTc have previously been encapsulated inside of 
fullerenes, which could potentially be used for SPECT imaging [150-152]. Moreover, various 
radionuclide-based imaging agents – providing different half-lives and energy level – can be 





Photothermal Therapy (PTT) 
 Carbon nanomaterials have also been actively explored for therapeutic uses. For 
example, their high optical absorbance in the NIR region have allowed carbon nanomaterials 
to be applied for PTT. The process involves the local conversion of photon energy to thermal 
energy (over 40 °C) to destroy diseased cells [153]. This therapeutic option is particularly 
useful for cancer treatment as cancer cells are more vulnerable to hyperthermia by virtue of 
their decreased blood supply compared to normal cells [154]. Followed by NIR irradiation, 
several groups demonstrated the efficacy of CNT-based PTT in tumor-bearing mice models 
[155-157].  Robinson et al. described that CNT-based PTT was more effective than commonly 
used PTT agents (e.g., gold nanorods) in regards to achieving similar efficacy at lower doses 
and less laser power [158].  
 Yang et al. tried a similar experiment with GONs. They showed that GON-based PTT, 
intravenously administered, efficiently reduced tumor volume and greatly improved survival, 
likely due to the passive targeting effect [159]. The following study by Markovic et al. insisted 
that GONs could induce better PTT effect than CNTs owing to better dispersibility based on 
thermodynamic, optical and geometrical calculations [160]. Though fullerenes have not been 
heavily investigated for this therapeutic application, there are some studies that validate 
fullerene-based PTT. Krishna et al. demonstrated that some functionalization, such as 
polyhydroxy fullerenes or carboxy fullerenes, could induce photothermal effect with practical 
laser energy whereas pristine fullerenes and activated carbon could not [161]. In their follow 
-up study, they demonstrated the efficacy of fullerene-based PTT in a tumor-bearing mice 
model [127]. Likewise, graphitic-structured MCNs drew a photothermal effect from strong 
NIR light absorption and showed efficient photothermal conversion properties. With these 
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findings, Xu et al. asserted that MCNs were efficient and superior PTT agents in comparison 
to rGONs [105]. 
 
Photodynamic Therapy (PDT) 
 PDT is similar to PTT in the sense that it utilizes photon energy, but differs in its 
adoption of a photosensitizer (PS) (e.g., porphyrin, Chlorin e6) to produce an oxygen singlet 
or ROS, to trigger apoptosis of nearby cells [162]. Not only can carbon nanomaterials be used 
as a PS delivery platform, but also can also function as a PS themselves [108, 163]. For the 
purpose of CNT-based PDT, initial studies involved the delivery of photosensitizers [164, 165]. 
However, Wang et al. suggested the use of CNTs as a photosensitizer and showed that both 
covalently and non-covalently functionalized CNTs could generate the photodynamic effect 
with visual light [163]. Though GONs have not been reported as photosensitizers themselves, 
they have been frequently selected as PS delivery carriers. Rong et al. loaded photosensitizers 
(Photochlor® ) by ᴨ-ᴨ stacking, and results showed tumor shrinkage and improved survival after 
PDT treatment with in vivo models [166].  
 Fullerenes are widely known as effective photosensitizers because they are more 
photostable and exhibit less photobleaching compared to many available PS [167]. In addition, 
they are capable of producing both free radicals and ROS, while some PS can produce only 
one or the other. Therefore, they are the most actively investigated carbon nanomaterials for 
this therapeutic strategy. Tabata et al. attached PEG to fullerenes, to enhance dispersibility, and 
injected the formulation intravenously into tumor-bearing mice [168]. Results showed that 
fullerene-based PDTs successfully suppress tumor growth and that this effect is superior to a 
commonly used PS, Photofrin® . A marked drawback of exploiting fullerenes in PDT is their 
lower range of optical absorption in the visible region, which significantly limits in vivo 
application owing to the issue of tissue penetration [167]. To extend their absorption spectra 
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into the red/NIR region, attaching another PS (e.g., Chlorin e6) and optical clearing agents on 
fullerenes have been proposed as possible options [169-171]. 
 
Drug Delivery  
 As briefly introduced above, carbon nanomaterials hold great promise for drug delivery 
applications based on their ability to cross cell membrane, their improved pharmacokinetics 
and biodistribution, the ease of surface modification, good biocompatibility, large loading 
capacity and tunable drug release [77, 172, 173]. Doxorubicin (DOX), as a popular example, 
can be strongly associated with CNTs via ᴨ-ᴨ stacking. According to Liu et al., DOX loading 
to CNTs can be achieved up to 400 w/w% capacity compared to only 8-10 w/w% Dox loading 
capacity with conventional liposomes. Furthermore, release profile of the CNT-DOX complex 
can be tuned by altering the pH [108, 174]. By taking an advantage of the CNT-based delivery 
system, other cancer chemotherapeutics have been loaded to CNTs by either covalent or non-
covalent method; these endeavors have exhibited promising efficacy [89]. For example, Liu et 
al. conjugated water-insoluble paclitaxel (PTX) to the surface of CNTs by a cleavable linker. 
Cargo was released at the target site and results showed better efficacy in breast cancer-bearing 
mice compared to clinically approved Taxol®  [175]. Due to the structural similarity with CNTs, 
similar approaches have been explored with GONs [89, 176]. In such a way, diverse small 
molecules (e.g., antimicrobials, anti-inflammatory drugs, boron neutron capture agent) as well 
as large molecules (e.g., peptides, proteins) can be delivered with both CNTs and GONs [80, 
172, 177, 178]. 
 While there are some publications describing the use of fullerene-based drug delivery 
systems, investigation in this area is less prevalent compared to other carbon nanocarriers 
[179]. The small size of fullerenes (~ 1nm) is a major hindrance for this application, as 
nanocarriers smaller than ~ 5 nm are quickly cleared by the kidney [77, 180]. To overcome this 
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obstacle, some research groups prepared fullerene aggregates which were approximately 50-
200 nm in size in order to avoid renal clearance and take advantage of the enhanced 
permeability and retention (EPR) effect [181, 182]. With this method, Shi et al. conjugated 
polymers (PEI) and chemotherapeutics (docetaxel) to form a monodispersed and 
approximately 140 nm-sized fullerene aggregates and utilized this efficacious platform for 
treating cancer in a mouse model [181].  
 For drug delivery purpose, MCNs are usually compared with MSNs as a classification 
of porous materials, instead of other carbon matrices. In addition to the aforementioned 
advantage (better biocompatibility), MCNs are preferred over MSNs because of their higher 
surface area and, resulting in larger drug loading capacity [183]. Based on lessons learned from 
CNTs and GONs, Zhu et al. loaded DOX on MCNs using ᴨ-ᴨ interactions and showed a pH-
dependent release profile, endocytosis and beneficial tumor-killing effect with in vitro 
experiments [74]. Gu et al. selected another chemotherapeutic (camptothecin) for MCN-based 
drug delivery system, and confirmed that carbon matrices offered a 1.7-fold increased loading 
capacity over MSNs [183]. Exploiting the high NIR absorbance of MCNs, other studies 
demonstrated a controlled release of drug by heat generation and explored applications of 
chemo-photothermal therapy [105, 113]. Wan et al. loaded PTX on PEI-functionalized MCNs 
and attached targeting ligands (folic acid) for active tumor targeting. Results showed superior 
efficacy compared to in vivo control groups [184]. 
 
Gene Delivery 
 Gene therapy provides a promising avenue for the treatment of diverse cancer types as 
well as genetic disorders that have no other therapeutic options. Poor pharmacokinetic profile 
and easy degradation by nucleases are common limiting factors for current gene therapies (e.g., 
small interfering RNA (siRNA), plasmid DNA (pDNA), antisense oligonucleotides). 
26 
Alternative delivery systems have been explored to overcome these issues [185]. In spite of 
lower transfection efficiency compared to viral vectors, non-viral vectors – including carbon 
nanomaterials – can possess lower immunogenicity while contributing potential for higher 
payload loading and scale-up [186-188]. Positive charges must generally be induced on carbon 
nanomaterials by functionalization so that they can bind to negatively charged DNA or RNA 
through electrostatic interactions. Though the first study of CNT-based gene delivery systems 
was able to enhance gene expression up to 10 times more than pDNA alone, researchers used 
beta-galactosidase as a proof-of-concept [189]. Another study conducted by Liu et al. showed 
that siRNA was successfully delivered with CNTs to transfected human T and primary cells, 
which has been a challenging task for non-viral vectors [190]. Later, McCarroll et al. and many 
others demonstrated the potency of CNT-based gene delivery system at an in vivo level [191, 
192].  
 Since early studies of carbon nanomaterial-based gene therapy were investigated with 
CNTs, experiments have been repeated, and further improved upon, with GONs. Due to the 
inherent negative charge of unmodified GONs, both charge masking and introducing positive 
charge are imperative for condensing genetic cargos. PEI is a cationic polymer which has been 
extensively used in gene therapy by virtue of its high transfection efficiency, but the toxicity 
of the polymer itself has limited its applicability [108]. Feng et al. conjugated PEI to load genes 
(pDNA and siRNA) and PEG to enhance biocompatibility on GONs; findings showed 
outstanding transfection efficiency while reducing cytotoxicity of the polymer [193]. Thus, a 
large portion of GON-based gene therapy has exploited the GONs-PEI platform. 
 With regard to numerous gene delivery publications utilizing other carbon 
nanomaterials, fullerene-based gene therapy so far has received little attention. Besides the 
aforementioned issue of small size, fullerenes also carry a large price tag. In the past decade, 
the price has been lowered; it is thought to be a more accessible option in the near future [194]. 
27 
Nevertheless, a study by Nakamura et al. pioneered the application of tetracationic fullerenes 
to induce strong association with double-stranded pDNA [195]. The group successfully 
transfected green fluorescent protein (GFP) to mammalian cells for the first time with 
fullerenes; this efficiency was comparable to the commercial agent (lipofection). Ten years 
later, the same group slightly modified the formulation and demonstrated the feasibility with 
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Table 1.1 Candidates of neutron-activatable radionuclides. Radioactivity was calculated with 
irradiation of 1 g of natural abundance element for 1 h in a neutron flux of 5.5 x 1012 neutrons 












89Y/90Y 100 1.28 64.1 2.28 (β) 12.6 
144Sm/145Sm 3.07 1.6 8160 0.06 (γ) 0.234 
150Sm/151Sm 7.38 103 788400 0.076 (β) 0.003 








197Au/198Au 100 98.7 640.7 0.96 (β) 434.4 





















 Neutron-activation is a promising method of generating radiotherapeutics with minimal 
handling of radioactive materials by medical providers. Graphene oxide nanoplatelets (GONs) 
were examined as a carrier for neutron-activatable holmium for theranostic application. GONs 
have desirable characteristics as a theranostic agent such as a rigid structure, high metal loading 
capacity, low density, heat resistance, and the ability to withstand harsh environments 
associated with the neutron-activation process. Non-covalently PEGylated GONs (GONs-PEG) 
offered enhanced dispersibility and biocompatibility, and also exhibited increased holmium 
loading capacity nearly two-fold greater than unfunctionalized GONs. Holmium leaching was 
investigated in vitro over a wide pH range, including conditions that mimic the tumor 
microenvironment, following neutron irradiation. Cell-based cytotoxicity analysis of the GON-
based formulations with non-radioactive holmium confirmed low cytotoxicity. These results 




                                                 
1 Part of this chapter was submitted as an article to the Nulear Medicine and Biology as follows: 
J. Kim, M. Jay “Neutron-Activatable Radionuclide Cancer Therapy Using Graphene Oxide 
Nanoplatelets.”, Nuclear Medicine and Biology (under revision). 
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2.2 Introduction 
 With the advent of the nano-revolution, carbon-based nanomaterials have gained much 
attention from various fields, and nanomedicine was not the exception [1]. Specifically, carbon 
nanotubes and fullerenes have been the initial subject of much attention owing mostly to their 
unique physical and chemical characteristics [2, 3]. Soon after the isolation of graphene by 
Geim and Novoselov in 2004, this material arguably became the ‘hottest’ carbon-based 
nanomaterial. Once called “the thinnest material in the universe and the strongest ever 
measured” [4], graphene has a myriad of attractive qualities: an extremely large surface area, 
chemical and mechanical strength, and superior thermal and electrical conductivity [5-7].  
 In the field of nanomedicine, graphene oxide nanoplatelets (GONs) are a preferred 
choice as a drug delivery system, because the hydrophobic nature of graphene makes it difficult 
to disperse in aqueous solvents [8]. Two specific findings dramatically increased the potential 
of GONs as a drug delivery carrier: that they are biocompatible with functionalization (e.g., 
with polyethylene glycol (PEG)), and they exhibit π–π stacking with aromatic-structured 
chemotherapeutics (e.g., doxorubicin) leading to exceptionally high loading capacity (400 
w/w%) [9, 10]. In addition, high propensity for metal adsorption is an additional feature that 
makes them an attractiv carrier for therapeutic radionuclides. In one study, graphene oxide was 
reported to adsorb a 10-fold higher amount of copper ion compared to activated carbon, which 
has been a heavily investigated material for adsorbents by virtue of large surface area [11]. 
While there have been a number of published studies assessing the merits of GON-based 
delivery of small molecules (e.g., SN38, camptothecin analog, paclitaxel, cisplatin), as well as 
large molecules (e.g., vaccines, proteins, genes), publications detailing their utility for delivery 
of radionuclides are scarce [12-17]. 
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 The conventional methods of preparing radiotherapeutics begin with a radioactive 
isotope which is then conjugated or loaded onto a carrier (e.g. liposomes, polymeric micelles, 
peptides, or proteins) [18-21]. This method requires the researcher to deal with highly 
radioactive materials from the very start of the formulation preparation process. Neutron 
activation – a process by which stable isotopes are converted into radioactive isotopes through 
the capture of an additional neutron – is a promising approach to minimize the direct handling 
of radioactivity. Moreover, this strategy is able to offer the additional benefits of minimal use 
of excipients being able to control the amount of radioactivity produced by varying the neutron 
flux or irradiation time. In spite of these advantages, the neutron-activation process has not 
been widely utilized for the production of radiotherapeutics. This is because a significant 
amount of heat is generated during the neutron-activation process which may result in the 
degradation of conventional nanocarriers [22]. To overcome this, Di Pasqua et al. previously 
explored the application of mesoporous silica nanoparticles (MSNs) as neutron-activatable 
radionuclide carriers. These carriers were found to be able to withstand the harsh environment 
required for neutron-activation [23]. However, the relatively high density of the formulation 
has limited their utility to intraperitoneal administration.  
 In the current study, GONs were investigated as a lower density and more durable 
alternative to MSNs for neutron activation and delivery of radionuclides. Among the possible 
neutron-activatable radionuclide candidates, holmium (Ho) was selected for the current study. 
Ho possesses desirable characteristics for the proposed application, including its high natural 
abundance (165Ho can only be activated to 166Ho) and its large neutron capture cross-section 
(64 barns, cf. 1.3 barns of 89Yttrium where 1 barn = 10-24 cm2) [24-26]. Once stable Ho is 
activated, 166Ho decays by emission of high energy β- particles (Emax= 1.84 MeV, 8.7 mm 
maximum tissue penetration) and low energy γ-photons (81 keV, 6.7% photon yield) which 
allow for its theranostic application via SPECT/CT imaging (Fig. 2.1) [27, 28]. Also, its 
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relatively short half-life (26.8 h) reduces the concern of radioactive retention in the human 
body for extended periods of time. In this chapter, GONs were investigated as a carbon-based 
carrier for radiotherapeutics that could be loaded in a shorter period of time as well as to achieve 
better tumor penetration. The successful development of GONs as a neutron-activatable Ho 
matrix is projected to be utilized for radionuclide therapy which can potentially target multiple 
targets. 
 
2.3 Materials and Methods 
2.3.1 Chemicals 
 Graphite flakes, hydrogen peroxide (30%, USP testing grade) and holmium (III) acetate 
monohydrate (99.99%) were acquired from Sigma-Aldrich (St. Louis, MO). Sulfuric acid 
(ACS grade), sodium nitrate (analytical grade), sodium hydroxide (ACS grade), nitric acid 
(trace metal grade) and potassium permanganate (reagent grade) were obtained from Fisher 
Chemical (Fair Lawn, NJ). 1,2-distearoyl-sn-glycero-3-phospho-ethanolamine-N-[methoxy 
(polyethylene glycol)-3000] (DSPE-PEG) was purchased from Avanti Polar Lipids Inc. 
(Alabaster, Alabama).  
 
2.3.2 Synthesis of GONs 
 GONs were synthesized based on a modification of the graphite flake oxidation and 
ultra-sonication method established by Tour et al. [29]. Briefly, graphite flakes were sieved 
through a U.S. standard testing sieve (300 µm). A 9:1 mixture of H2SO4 and H3PO4 (400 mL) 
in addition to 18 g of KMnO4 were added to 3 g of sieved graphite flakes and stirred for 12 h 
at 50 °C. When the reaction had cooled to room temperature (taking on a purple color), 400 
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mL of Milli-Q water and 3 mL of 30% H2O2 were added. The mixture was sieved again (300 
µm) and filtered through the polyester fiber. The resultant yellowish filtrate was centrifuged at 
2400 x g for 2 h. The filtrate was washed with Milli-Q water, 30% HCl and ethanol (2 times) 
to remove unreacted precursors, and the washed product was vacuum-dried overnight at room 
temperature. Graphene oxide was further exfoliated and reduced to nano-size GONs by 2 h of 
sonication with probe sonicator (Fisher Scientific Model 505 Sonic Dismembrator; power: 500 
watts, operating frequency: 20 kHz and amplitude: 25%). For additional purification, GONs 
were centrifuged at 1800 x g for 5 minutes and the supernatant was dialyzed for 3 days before 
their use (MWCO: 12 KDa). 
 
2.3.3 Non-covalent PEGylation on GONs  
 In order to enhance colloidal stability and biocompatibility, GONs were PEGylated by 
a non-covalent method. Since DSPE-PEG was stored in chloroform, the solvent was 
evaporated and DSPE-PEG was re-suspended in Milli-Q water. Ten mL of GONs (0.5 mg/mL), 
suspended in Milli-Q water, were mixed with 5 mL of DSPE-PEG (2.5 mg/mL) and sonicated 
for 10 minutes. The unreacted precursor was removed by centrifugal filtration (3 times, MWCO: 
50 KDa).  
 
2.3.4 Physicochemical characterization of GONs 
 Fourier transform infrared spectroscopy (FTIR; Thermo Nicolet 380) was used to detect 
representative functional groups of graphite and GONs. The conversion of graphite to GONs 
was confirmed by X-ray powder diffraction (XRD; Rigaku Multiflex X-ray diffractometer with 
Cu Kα radiation (λ= 1.5418 Å )). The polydispersity index (PDI) and zeta potential of the GONs 
were measured using a Malvern Zetasizer Nano ZS. The morphology and thickness of GONs 
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were observed by atomic force microscopy (AFM; Asylum Research MFP3D Atomic Force 
Microscope), and size distribution was calculated from AFM images by ImageJ.  
 
2.3.5 Holmium loading on GONs  
 Holmium acetate (Ho(Ac)3) was added to either GONs or non-covalently PEGylated 
GONs (GONs-PEG). Three different loading methods – simple vertexing, short sonication (1-
5 minutes), and stirring for 24 h – were compared. To ensure complete loading of Ho on the 
GON preparations, subsequent experiments were conducted using the short sonication method 
(5 minutes). To estimate the maximum loading of Ho on the GON preparations, varying 
amounts of Ho were mixed with the GONs and unbound Ho was removed by centrifugal 
filtration (MWCO: 50 KDa). The experiment was conducted with 166Ho and the amount was 
quantified by a γ-counter (PerkinElmer 2470 Wizard γ-counter). The Ho loading capacity was 
also verified by inductively coupled plasma mass spectrometry (ICP-MS; Agilent 7500cx with 
Agilent 1260 Infinity Bioinert LC). 
 
2.3.6 Holmium desorption from GONs in various pH 
 166Ho-GONs or 166Ho-GONs-PEG (0.5 mg of GONs/mL) were added to a range of pH 
solutions which were adjusted by sodium hydroxide and nitric acid titration. Solutions were 
stirred for 24 h at 100 rpm and then leached 166Ho was separated by centrifugal filtration 





2.3.7 In vitro leaching study 
 Two hundred µL of 166Ho-GONs or 166Ho-GONs-PEG (0.5 mg of GONs/mL) were 
placed in a dialysis cup (Slide-A-Lyzer MINI dialysis® , 3500 MWCO) which was subsequently 
dialyzed against 20 mL of phosphate buffered saline (PBS) at 37 °C and shaken at 100 rpm 
(Thermo MAXQ 4450). A sample of the dialysate was drawn at pre-determined time points (1, 
3, 6, 12, 24, 36 and 48 h) and the leached amount of 166Ho was quantified with a γ-counter. 
 
2.3.8 Stability of neutron-activated Ho-GONs-PEG 
 Freeze-dried 165Ho-loaded GONs-PEG were irradiated for 1 h in the PULSTAR Reactor 
Facility at The North Carolina State University (reactor power = 1 MW; thermal neutron flux 
= 5.5 x 1012 neutrons cm-2 s), and the leached 166Ho was separated by centrifugal filtration 
(MWCO: 50 KDa) and quantified by γ-counter. The exact amount of Ho in the Ho-GONs-PEG 
was determined by neutron-activation analysis (NAA). An ORTEC 42% high purity 
germanium detector system with a Canberra AFT research amplifier, multi-port II analog-to-
digital converter and Genie 2000 MCA spectroscopy software was utilized to quantify the 
amount of 166Ho produced by neutron-activation, which was adopted for back-calculating the 
amount of 165 Ho in the formulation. 
 
2.3.9 In vitro cytotoxicity evaluation 
 Three non-radioactive GON-based formulations (GONs, 165Ho-GONs and 165Ho-
GONs-PEG) were tested in a human ovarian cancer cell line (A2780) to assess the cytotoxicity 
of the formulation components. The ovarian cancer cells were cultured in RPMI-1640 medium 
with 10% FBS and 1% penicillin-streptomycin in 5% CO2 at 37 °C. When cells became 
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confluent, they were seeded in a 96-well plate (5000 cells/well) and incubated for 24 h. Each 
well was treated with a pre-determined amount of formulation and cultured for 24 h or 48 h. 
After removing the formulations and washing with sterile PBS, the media (100 µL/well) and 
cell counting kit-8 (CCK-8) reagents (10 µL/well, Dojindo Laboratories) were added. Cells 




2.4.1 Characterization of GONs 
 To confirm the successful oxidation of graphite, representative functional groups of 
GONs were analyzed by FTIR (Fig. 2.2a). The O-H stretching band of the GONs was observed 
between 3000 cm-1 and 3500 cm-1. The C=O stretching region of carboxylic groups and the C-
O-C stretching band of the epoxide groups were seen at 1725 cm-1 and 1052 cm-1, respectively. 
A change of XRD pattern from graphite to GONs also supported the successful synthesis (Fig. 
2.2b). To exploit passive targeting via the enhanced permeation and retention (EPR) effect, 
GONs were reduced to nano-size by sonication and they were shown to have an irregular shape 
with a wide size distribution (136.7 ± 85.2 nm) (Fig. 2.3a,c) [30]. The approximate 1.2 nm 
height of GONs suggested that they were successfully separated from stacked graphite to a 
single-layered graphene structure, which matches previous reports (Fig. 2.3e) [29]. The PDI 
and surface charge measurement by zetasizer exhibited monodispersity (0.230 ± 0.006) and a 




2.4.2 Surface modification of GONs 
 To obtain a narrow size distribution, solutions were centrifuged to eliminate large-sized 
GONs, and resulting supernatant portion was used in the PEGylation process. GONs-PEG were 
shown to have narrower size distribution (62.1 ± 14.0 nm) (Fig. 2.2b,d). The non-covalent 
attachment of PEG resulted in an increased cross-section height to ~14 nm and a slight 
improvement in the PDI (0.185 ± 0.003) (Fig 2.3f).  
 
2.4.3 Holmium loading on GONs  
 Three methods were evaluated for loading GONs with Ho(Ac)3; and no significant 
difference in loading capacity and efficiency were observed. As shown in Fig. 2.4, GONs was 
able to maintain their dispersibility until the weight ratio of GONs:Ho(Ac)3 reached 1:0.1, at 
which point above this holmium ratio, the suspensions were observed to aggregate.  Based on 
ICP-MS analysis, the maximum loading capacity of holmium on GONs that could maintain 
dispersibility was determined to be 4.38 w/w %.  When PEGylated, GONs maintained their 
dispersibility even at GONs:Ho(Ac)3 ratios of 1:0.2. The maximum holmium loading on 
GONs-PEG was evaluated by NAA and determined to be 8.38 w/w %.   
 
2.4.4 Holmium sorption on GONs  
 The binding of holmium on GONs was evaluated within pH range of 1 to 14. The 
sorption profiles of GONs and GONs-PEG were not significantly different based on two-way 
ANOVA analysis. Almost all of the Ho was bound to GONs and GONs-PEG (> 98%) between 
pH 4-14 (Fig. 2.5). However, as oxygen-containing functional groups of GONs were 
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protonated in acidic pH, sorption of Ho decreased as the pH. Only ~16% of holmium was 
bound to GONs and GONs-PEG at pH 1.  
 
2.4.5 In vitro leaching assessment 
 As expected, there was almost no Ho leaching observed at physiological pH (7.4) until 
12 h after incubation (Fig. 2.6). After 48 h, only 10% of Ho leaching was observed. Unlike 
GONs, GONs-PEG did not show any Ho leaching at pH 7.4 even after long incubation times. 
Under slightly acidic conditions (pH 5.5), GONs and GONs-PEG exhibited sustained-release 
profiles that were not significantly different.  
 
2.4.6 Stability of neutron-activated GONs 
 The critical parameter to be assessed for carriers of neutron-activated radiotherapeutics 
is the leaching of radioactivity following neutron irradiation which may result in degradation 
of GONs in the relatively harsh reactor environment during the irradiation process. As the 
ultimate goal is to deliver therapeutic radionuclides to target tissues (e.g., tumors), a minimal 
amount of leaching of the radionuclide (166Ho in this application) is desirable to prevent off-
target accumulation of the released radionuclide.  The non-radioactive Ho-loaded GONs and 
Ho-loaded GONs-PEG were irradiated in a neutron flux for 1 h and washed 3 times with Milli-
Q water. Only very small amounts (<0.1% of the total radioactivity) of 166Ho could be detected 
in the washings which indicated that leaching of radioactive holmium from these irradiated 




2.4.7 In vitro cytotoxicity evaluation 
 The viability of a human ovarian cancer cell line (A2780) following exposure to various 
concentrations of GONs, Ho-loaded GONs (165Ho-GONs), and Ho-loaded GONs-PEG (165Ho-
GONs-PEG) was assessed.  GONs did not induce any cytotoxicity at concentrations up to 10 
µg/mL when incubated for 24 h or 48 h, and the addition of Ho and PEG did not add increase 
the toxicity of the carriers (Fig. 2.7).  
 
2.5 Discussion 
 In this study, GONs were explored as a neutron-activatable radionuclide carrier. The 
successful synthesis of GONs was confirmed by FTIR, XRD and AFM. For a GON-based 
formulation, surface modification was necessary for passive tumor-targeting effects [31]. 
Previous studies have demonstrated that GONs undergo irreversible aggregation without 
proper capping agents [32-34]. The PEG moiety is generally recognized as safe (GRAS) by the 
U.S. Food and Drug Administration (FDA) and is frequently employed for enhancing both 
biocompatilibity and dispersibility of nano-carriers in biological systems [35]. Covalent and 
non-covalent PEGylation strategies were evaluated with the latter ultimately being selected 
based on ease of the method and the short reaction time (10 minutes of sonication) to exploit 
the strong association between the phospholipid portion of DSPE-PEG and the aromatic 
moieties of GONs. 
 Among the different forms of holmium, Ho(Ac)3 was selected for incorporation into 
GONs. Ho(Ac)3 is a preferred load versus Ho(Cl)3, as the acetate form does not contain readily 
activatable nuclei, while radioisotopes of Cl can form upon neutron irradiation of Ho(Cl)3. 
Other investigators report the use of cargo loading methods that require incubations for an 
extended period of time [36-38]. Since GONs are known to possess a large surface area, it was 
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assumed that the Ho loading process would proceed more rapidly with GONs compared to 
other nanocarriers. There was no significant difference between the three loading methods in 
terms of loading capacity or efficiency in GONs:Ho(Ac)3 ratios tested. These results suggest 
that Ho associated quickly with GONs. Holmium binding on GONs is facilitated mostly 
through electrostatic interaction with the negatively-charged oxygen-containing functional 
groups on GONs; electrostatic repulsion results in a stable dispersion between resulting layers 
[39]. As these negatively charged groups are masked by Ho binding, products started to show 
aggregation at GONs:Ho(Ac)3 ratios above 1:0.1. Since PEGylation was able to offer 
additional dispersibility even after the charge masking, Ho-GONs-PEG did not aggregate with 
higher Ho ratios, and Ho loading capacity increased from 4.38 (w/w) % to 8.38 (w/w) %.  
 Ho sorption was investigated over a wide pH range. Some elements such as U(IV), 
Sr(II), Tc(VII) and Np(V) have weaker and more pH-dependent association with graphene 
oxides compared to others [40]. Since GONs were not covalently PEGylated in this study, the 
functional groups of GONs were still intact following PEGylation. Hence, there was no 
significant difference in Ho sorption between GONs and GONs-PEG. The result of this 
sorption experiment showed a similar pH-dependent pattern – Ho sorption was nearly complete 
at pH ≥4, and significant leaching was seen in acidic conditions  - in comparison to other heavy 
metals (Th(IV), Pu(IV), Am(III), Eu(III)) [40].   
 Although the sorption experiment demonstrated a strong binding affinity between Ho 
and GONs, this complex was further evaluated in conditions that mimic the tumor 
microenvironment. While the pH of human body fluid is well-regulated by homeostasis to be 
maintained at pH 7.4, the pH of the tumor microenvironment is slightly acidic (pH 5.5 to 7.0) 
due to glycolytic metabolism, hypoxia, and deficient blood perfusion [41, 42]. Although Ho 
was shown to bind to GONs quantitatively at pH >4 in the sorption study, holmium was 
observed to be slowly released from the GONs in the leaching study when the pH of the 
55 
medium was 5.5 due to a change in equilibrium resulting from the larger volume of dialysate 
in the leaching study. The faster release rate at pH 5.5 compared to pH 7.4 was likely due to 
protonation effects at the lower pH. Considering that Ho did not leach from the GONs-PEG at 
pH 7.4 after a long incubation time, DSPE-PEGylation was considered as a means to offer an 
additional barrier to holmium loss, but this effect was diminished in acidic conditions (pH 5.5).  
 One well-known limitation of nanocarrier-based drug delivery system is tumor 
penetration. A considerable portion of administered nanoparticles remains near blood vessels 
instead of penetrating into deep tumor region which often causes a sub-therapeutic effect. 
Cabral et al. showed that smaller nanoparticles (30 nm) were able to penetrate tumor tissue 
more efficiently than larger nanoparticles (50-100 nm); Wong et al. reported that 10 nm 
nanoparticles in the tumor microenvironment were capable of reaching deeper tumor sites than 
100 nm nanoparticles [43, 44]. Based on these reports, the sustained holmium desorption in a 
mildly acidic environment may confer improved deep tumor penetration in vivo. Lastly, the 
safe toxicity profile of GON-based formulations (with non-radioactive holmium) verified that 
the tumor killing effect would exclusively result from the high energy of β- particles emitted 
by 166Ho and not by the toxicity of GONs themselves. 
 Overall, non-radioactive Ho-loaded GONs-PEG did not show any GONs-related 
cytotoxicity at concentrations up to 10 µg/mL for 48 h. After 1 h of neutron irradiation which 
produced radioactive holmium, no leaching of 166Ho was observed when the 166Ho-GONs-PEG 
were incubated at pH 7.4 for extended periods of time. The results suggest that Ho-loaded 
nanocarriers will stay intact not only during preparation, but also in the circulation in vivo after 





 Graphene oxide nanoplatelets (GONs) were evaluated as a neutron-activatable 
holmium carrier for theranostic application. GONs were synthesized from graphite and 
subsequently characterized. Through non-covalent PEGylation, their dispersibility and 
biocompatibility were improved, and the Ho-loading capacity increased nearly two-fold 
(w/w %). Leaching of radioactive holmium following neutron irradiation of Ho-GONs-PEG 
was minimal for 48 h which is almost two half-lives of the radionuclide. The safety of this 
formulation was supported by in vitro cytotoxicity assays in a human ovarian cancer cell line. 
As a platform technology, the neutron activation approach using GONS as the carrier is 
applicable for several therapeutic radionuclides such as 90Y, 153Sm, 177Lu, 188Re and 198Au. 
GONs can also be used as a matrix for other therapeutic radionuclides by virtue of their ability 
to avidly adsorb a variety of metals. The adsorption of high-specific activity radioactive metals 
like 89Sr and 90Y to GONs would add an extra handling step, but would avoid the logistical 
issues of the neutron activation approach such as the availability of a high flux neutron source 
(e.g., a nuclear reactor). Further experimentation would be required to determine if GONs could 
be used as carriers for radiotherapeutic anions like [32P]-phosphate or [131I]-iodide. If the 
stability of chemotherapeutics entrapped within Ho-GONs-PEG can be confirmed following 
neutron irradiation, a combination therapy approach (chemoradiotherapy) is anticipated to 
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Figure 2.3 Characterization of GONs and GONs-PEG by AFM. AFM images of (a) GONs and 
(b) GONs-PEG. Size distribution of (c) GONs and (d) GONs-PEG as estimated by ImageJ. 




Figure 2.4 Evaluation holmium loading on (a) GONs and (b) GONs-PEG (red box indicates 








Figure 2.5 Holmium sorption on GONs and GONs-PEG in a wide range of pH. Groups were 




Figure 2.6 In vitro holmium leaching profile between GONs and GONs-PEG at pH 4.5 and 
7.4. Groups were compared by two-way ANOVA (** for p< 0.01 and **** for p< 0.0001). 
Each time point of same pH groups was analyzed by Bonferroni's multiple comparisons test (δ 





Figure 2.7 Viability of A2780 cells following 24 h (a) and 48 h (b) incubation of GONs and 





CHAPTER 3 IN-SITU FORMATION OF HOLMIUM OXIDE IN PORES OF 




 Radionuclide therapy with nano-sized carriers is a very promising approach to treat 
various types of cancer. The preparation of radioactive nanocarriers can be achieved with 
minimum handling using a neutron-activation approach. However, the nanocarrier material 
must possess certain characteristics such as low density, heat-resistance, high metal adsorption, 
easy surface modification and low toxicity in order to be useful. Mesoporous Carbon 
Nanoparticles (MCNs) in which holmium oxide is formed in their pores by a wet-impregnation 
process were investigated as a suitable material for this application. Holmium (165Ho) has a 
natural abundance of 100% and possesses a large cross-section for capturing thermal neutrons. 
After irradiation of Ho-containing MCNs in a neutron flux, 166Ho, which emits therapeutic high 
energy beta particles as well as diagnostic low energy gamma photons that can be imaged 
externally, is produced. The wet impregnation process (16 w/w% Ho loading) is shown to 
completely prevent the leaching of radioactive holmium from the MCNs without 
compromising their structural integrity. In vitro studies showed that the MCNs containing non-
radioactive holmium do not exhibit toxicity and the same formulation with radioactive 
                                                 
2 Part of this chapter previously appeared as an article in the Carbon. The original citation is as 
follows: J. Kim, J.-X. Luo, Y. Wu, X. Lu, M. Jay “In-Situ formation of holmium oxide in pores 
of Mesoporous Carbon Nanoparticles as substrates for neutron-activatable radiotherapeutics.”, 
Carbon 117 (2017) 92-99. 
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holmium (166Ho) demonstrated a tumoricidal effect. Post-irradiation PEGylation of the MCN 
surfaces endows dispersibility and biocompatibility. 
 
3.2 Introduction 
 A variety of materials has been used in the design of nanocarriers for delivery of 
therapeutic agents to target organs and tissues. These agents include drugs, vaccines and 
radionuclides that emit particulate (α or β-) radiation. For the latter application, creating 
nanocarrier materials containing large amounts of therapeutic radionuclides can be hazardous 
to the personnel involved in this process. This can be avoided by incorporating a carefully 
selected stable nucleus into the nanocarriers and subsequently exposing them to a high flux 
density of thermal neutrons such as is found in a nuclear reactor. If the stable nuclei have a 
sufficiently large thermal neutron capture cross-section, they can be activated to therapeutic 
(i.e., tumor cell killing) radioactive nuclei. This neutron-activation approach allows the stable 
isotope-containing nanocarriers to be produced without constraints related to handling 
hazardous radioactive materials or short isotopic half-lives. The nanocarriers can be subjected 
to neutron irradiation just prior to the time of administration to patients, thus limiting the 
handling of radioactive materials by personnel. For such an application, the nanocarrier 
materials must be able to entrap significant amounts of the stable isotope, withstand the harsh 
conditions in the core of a nuclear reactor, retain the radioactive isotope produced following 
neutron irradiation to prevent accumulation of the radionuclide in non-target tissues due to 
leaching, be of relatively low density for facile administration by the intravenous route, and be 
non-toxic. 
 Mesoporous Carbon Nanoparticles (MCNs) have been widely studied for use in a 
variety of applications including as fuel cells, supercapacitors, gas storage devices and as 
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catalysts, but only rarely for drug delivery applications. This is in contrast to other carbon-
based materials such as carbon nanotubes, fullerenes, graphene oxide nanoplatelets and carbon 
nanodiamonds, all of which have been used as drug delivery vehicles [1-4]. Zhu et al. explored 
the possibility of using MCNs for chemo-therapeutic drug delivery by exploiting the 
hydrophobic nature, large surface area, easy surface modification and low toxicity profile of 
MCNs [5]. A product known as Carbon Nanoparticles Suspension Injection (CNSI® ), which 
contain particles 150 nm in diameter, has been tested in human clinical trials and was approved 
as a lymph node tracer by the China Food and Drug Administration [6]. Interestingly, these 
carbon nanoparticles did not induce major toxicities or allergic reactions [7]. Here we report 
on the investigation of MCNs as a carrier of stable isotopes for subsequent conversion to 
radioactive isotopes following neutron irradiation. This neutron-activation approach allows the 
preparation of therapeutic radionuclides in carriers that can be targeted to tumors (requiring 
large amounts of radioactivity) with minimum handling by the operator. Among the potential 
candidates of stable neutron-activatable elements, holmium (165Ho) was chosen due to its high 
natural abundance (100%) and its large thermal neutron capture cross-section (64 barns where 
1 barn = 10-24 cm2) for activation to 166Ho. This radioactive isotope of holmium decays by the 
emission of high energy β- particles (Emax= 1.84 MeV) and γ-photons (81 keV, 6.7% photon 
yield) with a relatively short half-life (26.9 h). These properties make 166Ho suitable as a 
‘theranostic’ agent whereby the β- particles provide their tumor-killing radiotherapeutic 
function while the emitted γ-photons allows the biodistribution of 166Ho-labeled MCNs to be 
assessed noninvasively by SPECT/CT imaging (Fig. 3.1) [8, 9]. Indeed, a 166Ho/chitosan 
complex was formulated as a local tumor ablative agent in which their safety and efficacy were 
confirmed in a Phase IIb clinical study [10]. This formulation was approved under the brand 
name of Milican®  in 2001 by the Korea Food and Drug Administration [11]. While this 
formulation demonstrated potential as a radiotherapeutic agent, it was produced by the 
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cumbersome process of incorporating 166Ho into the formulation and not by neutron-activation 
of a 165Ho/chitosan complex. 
 When considering materials as suitable carriers of neutron-activatable elements, one 
must take into account the loading capacity of the carriers for these elements as well as their 
stability following irradiation in a nuclear reactor where the neutron flux density is great 
enough to yield therapeutically-sufficient amounts of the activated radionuclide. Holmium 
encapsulated polymeric microspheres comprised of poly (L-lactic acid) have been used as 
carriers of neutron-activatable elements, and one such composition is currently in clinical trials 
for treating liver cancer [8, 12]. In spite of successful translation to the clinic, the biggest 
drawback of this formulation is degradation of the polymer by heat generated during the 
neutron-activation process. This can lead to premature leaching of the activated radionuclide 
which can result in radioactivity accumulating in non-target tissues after administration to a 
patient. In order to reduce this degradation, shorter neutron irradiation times must be used; 
however, this limits the total amount of radioactivity that can be produced to potentially sub-
therapeutic levels. 
 Di Pasqua et al. explored the use of mesoporous silica nanoparticles (MSNs) as a carrier 
for neutron-activatable isotopes for intraperitoneal administration [9]. Because of our interest 
in using neutron-activated nanocarriers as a means to treat various types of cancers by systemic 
administration, high specific activities (mCi of 166Ho mg-1 of nanocarrier) are required. This 
means that long neutron irradiation times are needed to produce these high specific activities. 
Therefore, the nanocarriers required for this application need to have relatively high adsorption 
capacities for stable holmium and also need to be resistant to degradation in the relatively harsh 
nuclear reactor environment. In addition, it is desirable to avoid high-density nanocarriers to 
prevent settling of the particles during administration through an indwelling catheter. MCNs 
appeared to be an excellence choice as a nanocarrier for this theranostic application due to their 
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desirable characteristics of lower toxicity than MSNs, heat resistance and high metal adsorption 
capacity [13-15]. Nanocarriers composed of mesoporous carbon were evaluated for their ability 
to serve as a suitable delivery vehicle for therapeutic radionuclides produced by neutron 
activation. Here we report that sufficient quantities of the stable isotope holmium (165Ho) could 
be incorporated into MCNs using a wet impregnation technique, and that minimal leaching of 
the radionuclide produced by neutron activation (166Ho) following irradiation in a nuclear 
reactor was observed. A novel nuclear magnetic resonance (NMR) method was used to 
characterize the pore size distribution of the prepared MCNs. In addition, an in vitro cell-based 
assay was used to confirm that these stable holmium-containing MCNs did not induce cellular 
toxicity and that MCNs containing radioactive holmium demonstrated a sufficient tumor-
killing effect. Furthermore, the surfaces of the MCNs were modified by the addition of a 
polyethylene glycol (PEG) moiety to allow them to be dispersed in physiological solutions for 
intravenous administration and as a means of improving their biocompatibility.   
 
3.3 Materials and Methods 
3.3.1 Chemicals 
 Phenol, Pluronic®  F127 (triblock copolymer consisting of poly(ethylene oxide)–
poly(propylene oxide)–poly(ethylene oxide)), holmium (III) nitrate pentahydrate and holmium 
(III) oxide were purchased from Sigma-Aldrich (St. Louis, MO). Sodium hydroxide was 
obtained from Fisher Chemical (Fair Lawn, NJ). Formaldehyde (37%, ACS Reagent Grade) 
was received from Ricca Chemical (Arlington, TX). Holmium (III) acetylacetonate 
(Ho(AcAc)3) was acquired from GFS Chemicals (Columbus, OH). 1,2-distearoyl-sn-glycero-
3-phospho-ethanolamine-N-[methoxy (polyethylene glycol)-3000] (DSPE-PEG) was 
purchased from Avanti Polar Lipids Inc. (Alabaster, Alabama).  
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3.3.2 Synthesis of MCNs 
 MCNs were synthesized from phenol formaldehyde resin by adopting the soft-template 
method of Zhao et al [16]. Briefly, phenol (0.6 g) was added to a mixture of formalin solution 
(2.1 mL) and sodium hydroxide solution (15 mL, 0.1 M), and stirred at 70 oC for 30 min at 360 
rpm. A solution containing 0.96 g of Pluronic®  F127 in 15 mL of Milli-Q water) was added to 
the reaction and the temperature was lowered to 66 oC. After 2 h, the mixture was diluted with 
50 mL of Milli-Q water and the reaction was stopped when a reddish solid precipitate appeared.  
After measuring the volume of the suspension, a 3.16-fold excess of Milli-Q water was added. 
A hydrothermal reaction was then conducted at 130 oC for 24 h. After multiple washings with 
Milli-Q water, carbonization was performed at 700 oC under argon gas for 3 h after which time 
the final product (MCNs) was collected [16].  
 
3.3.3 Wet impregnation on MCNs (WI-MCNs) 
 A wet impregnation (WI) approach was employed to produce MCNs from which 
entrapped holmium was less likely to leak. WI was accomplished by adding holmium nitrate 
pentahydrate (100 mg) and MCNs (10 mg) to 20 mL of ethanol and stirring for 24 h at room 
temperature. The suspension was then centrifuged at 2000 x g for 15 min and the supernatant 
was decanted to remove unbound holmium. The solids were held under vacuum at room 
temperature overnight; the temperature was subsequently raised to 400 oC for an additional 4 
h to form holmium oxide. Any holmium oxide formed outside of the MCNs was removed by 
centrifugal filtration (Ultracel® , 50K MWCO) [17]. For a control study, Ho(AcAc)3 was loaded 
to MCNs by a physical adsorption method (MCNs-Ho(AcAc)3). This was accomplished by 
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mixing 100 mg of Ho(AcAc)3 and 10 mg of MCNs in ethanol for 24 h at room temperature. 
After removing unbound Ho(AcAc)3, the mixture was dried in a vacuum oven overnight.  
 
3.3.4 Surface modification of MCNs (MCNs-PEG) 
 The surfaces of these WI-MCNs were modified through non-covalent PEGylation by 
exploiting hydrophobic interactions between the MCNs and a phospholipid-based PEGylating 
agent. This was accomplished by adding DSPE-PEG to MCNs suspended in water and 
sonicating the suspension for 10 min.  
 
3.3.5 Physicochemical characterization of MCNs 
 The hydrodynamic diameter and zeta potential of MCNs, WI-MCNs and WI-MCNs-
PEG samples were measured using a Malvern Zetasizer Nano ZS. Scanning electron 
microscopy (SEM; Hitachi S-4700) was used to obtain images of the particles. Elemental 
composition of samples was determined by X-ray photoelectron spectroscopy (XPS; Kratos 
Axis Ultra DLD). As part of the sample preparation process, a powder form of the MCNs and 
WI-MCNs was pressed into an indium foil; interference from indium in the XPS analysis was 
normalized (Table 3.1). Powder X-ray powder diffraction (PXRD; Rigaku Multiflex X-ray 
diffractometer with Cu Kα radiation (λ= 1.5418 Å)) was used to assess the structure of 
impregnated holmium oxide in the MCNs. 
 
3.3.6 Holmium loading on MCNs 
 The amount of holmium content was estimated by thermogravimetric analysis (TGA; 
TA Instruments Q50). A 5 mg sample of WI-MCNs or MCNs-Ho(AcAc)3 was heated from 25 
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oC to 1000 oC with a heating rate of 10 oC minute-1.  The holmium content of the MCNs was 
also determined by neutron-activation analysis utilizing the PULSTAR Reactor Facility at 
North Carolinas State University (reactor power = 1 MW; thermal neutron flux = 5.5 x 1012 
neutrons cm-2 s). An ORTEC 42% high purity germanium detector system with a Canberra 
AFT research amplifier, multi-port II analog-to-digital converter and Genie 2000 MCA 
spectroscopy software were used to quantify the amount of 166Ho produced which was then 
used to calculate the amount of holmium (165Ho) in the sample.  
 
3.3.7 Stability of MCNs following neutron irradiation 
 For assessing the stability and retention of holmium in the MCN formulations following 
neutron irradiation, samples were irradiated for 1, 5 and 10 h in the PULSTAR nuclear reactor, 
placed in centrifugal filter (Ultracel® , 50K MWCO) and centrifuged at 2500 x g for 20 minutes. 
The amount of radioactivity (166Ho) in the filtrate was measured using a γ-counter (PerkinElmer 
2470 Wizard γ-counter). 
 
3.3.8 Calculation of pore size distribution by NMR 
 The nanopore size, pore size distribution and pore volume were characterized using the 
NMR-based method of Wu et. Al [18]. The NMR measurements were performed on a 400 
MHz (1H frequency) pulsed NMR system at room temperature. Approximately 20 mg of MCN 
and holmium-loaded MCN powder samples were loaded into a 4 mm spinner followed by 
addition of approximately 35 mg of deionized water. The spinner was then tightly sealed to 
prevent water loss due to evaporation. A magic angle spinning (MAS) spectrum was obtained 
at ~7 kHz spinning by recording the free induction decay after a single 90-degree pulse (~5 s). 
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The last delay was set long enough (10 s, and T1 ~ 1.5 s) to ensure that the signal was fully 
recovered after each scan.  
 
3.3.9 Evaluation of in vitro leaching 
 An in vitro leaching study was performed with 166Ho in which 200 L of MCN-
Ho(AcAc)3-PEG and WI-MCN-PEG samples (0.1 mg/mL) were placed in a dialysis cup 
(Slide-A-Lyzer MINI dialysis® , 3500 MWCO) which was suspended in 20 mL of Phosphate 
Buffered Saline (PBS) at 37 oC and shaken at 100 rpm (Thermo MAXQ 4450). A sample of 
the dialysate was collected at each time point (1, 2, 3, 6, 12, 24 and 36 h) and the holmium 
content was quantified in a γ-counter.  
 
3.3.10 In vitro cytotoxicity and efficacy assessment of MCNs 
 The toxicity of each of the three MCN formulations was assessed in a human ovarian 
cancer cell line (A2780) using a CCK-8 assay kit (Dojindo Laboratories). The A2780 cells 
were cultured with RPMI-1640 medium with 10% FBS and 1% penicillin-streptomycin in 5% 
CO2 at 37 
oC. The cells (5000 cells/well) were seeded in a 96-well plate and incubated for 24 
h. Pre-determined amounts of the formulations were added to each well and cultured for 24, 48 
and 72 h. After the formulations were removed and the wells were washed with PBS, the CCK-
8 reagents (10 L/well) were added. The cells were then incubated for 4 h and the absorbance 
at 450 nm was recorded with a plate reader (SpectraMax M5). To calculate the cell viability, 




3.4 Results and Discussion 
 MCNs were successfully prepared using the soft template method [16]. Image analysis 
by SEM showed that MCNs were uniform and spherical in shape (Fig. 3.2a,b). The 
composition of MCNs was analyzed XPS and found to consist only of carbon (94.2%) and 
oxygen (5.8%) (Table 3.1). By dynamic light scattering (DLS) and zeta potential 
measurements, the MCNs were shown to have an average diameter of 154 nm, almost neutral 
in surface charge (zeta potential = -0.37 mV) and to be monodisperse (PDI = 0.152) (Fig. 1c). 
The Type IV isotherm curve obtained by nitrogen gas adsorption measurements was indicative 
of the mesoporous structure of the MCNs and, thus, were exhibited to have a large surface area 
(665.2 m2 g-1) as determined by Brunauer-Emmett-Teller (BET) (Fig. 3.3a). 
 Although the BET method has been widely used for characterization of porous carbon 
structures, the assumptions of BET theory have been questioned for micropores and mesopores 
because it tends to overestimate the specific surface area. Therefore, a newly developed NMR 
method, which is sensitive to pores less than ~3 nm, was used to characterize the pore size 
distribution of the MCNs [18, 19]. A typical NMR spectrum of a water/MCN mixture is shown 
in Fig. 3.3b. Intergranular water was used as the chemical shift reference (0 ppm) and the up-
field peak at -1.5 ppm was from water inside the nanopores whose peak shape was used to 
derive the pore size distribution. The pore size was calculated from the nucleus-independent 
chemical shift (NICS) value by the following equation, 
𝑑 = 𝐴1𝑒
𝛿/0.53 + 𝐴2𝑒
𝛿/3.7 + 𝑑0  
 where A1, A2 and d0 are empirical parameters depending on the carbon material 
synthesis condition. Because MCNs were carbonized at 700 oC, which led to a lesser degree of 
graphitization and a smaller NICS effect, these parameters were recalibrated (scaled by 0.75 
from a previous report whose carbon was prepared at 900 oC) so that the average pore size 
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matched the value reported in the literature [16, 18, 20]. The nanopore volume per gram of 










 where Ap is the peak area of water in the nanopores, Atot is the total peak area, mw is 
the total water mass in the spinner, ρw = 0.9 g cm
-3 is the nanoconfined water density and mMCN 
is the MCN mass in the spinner [18]. NMR analysis of water adsorption showed that the 
nanopore volume of MCNs was 0.69 cm3 g-1. The dominant pore size was 2.6 nm and the pore 
size distribution was narrow in that 95% of the pore sizes were between 2 and 4 nm (Fig. 3.2c). 
Intergranular pores were not considered because their contribution to the total surface area was 
negligible. 
 Initially, a hydrophobic form of holmium (Ho(AcAc)3) was used to load 
165Ho into 
MCNs by physical adsorption. The amount of holmium loaded into MCNs was estimated by 
TGA, exploiting the fact that all of the carbon components were removed by pyrolysis between 
400 oC and 600 oC, but holmium was retained even at 1,000 °C (Fig. 3.5). Holmium loading in 
the MCNs was determined to 6.96%. To maximize the loading of holmium as well as to prevent 
leaching, wet impregnation followed by a drying and calcination process was used to 
synthesize holmium oxide in the pores of the MCNs [17]. Although MCNs-Ho(AcAc)3 were 
able to retain 166Ho relatively well, intra-pore synthesis of holmium oxide by this technique 
was shown to essentially and completely prevent the leaching of radioactive holmium from 
these nanocarriers after they had been irradiated in the nuclear reactor for up to 10 h (Fig. 3.6).  
The particle size distribution and morphology of the WI-MCNs also did not change indicating 
that the structural integrity of the particles was not compromised by long irradiation times. The 
maximum loading of holmium by WI was determined to be approximately 14 w/w% by TGA 
and 18.2 w/w% by XPS (Table 3.1). The most accurate amount of holmium loading was 
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determined by neutron activation analysis (NAA). After 165Ho was converted to 166Ho in the 
nuclear reactor, the amount of holmium in the MCNs was calculated from the quantity of 
radioactivity (166Ho) produced. NAA calculations determined that holmium loading in the 
MCNs was 5.34 w/w% and 16 w/w% by the physical adsorption method and WI, respectively. 
The PXRD pattern of WI-MCNs showed that holmium incorporation in MCNs resulted in 
significant reduction in signal intensity (Fig. 3.4). When it was contrasted with commercially 
purchased holmium oxide, several representative PXRD peaks of holmium oxide were absent 
in the WI-MCNs, which indicated crystalline structured holmium oxide was not formed outside 
of the mesoporous system. The total surface area of the MCNs was significantly reduced from 
665.2 to 368.6 m2 g-1 after the WI procedure. This is likely due to the holmium oxide particles 
occupying space in the pores of the MCNs (Fig. 3.3a). This was also evidenced by the NMR 
characterization. MCNs showed two 1H peaks where the upfield peak (at -1.5 ppm) was from 
water in the nanopores. However, the nanoconfined water peak was absent in the NMR of the 
holmium impregnated MCNs, indicating occupation of the nanopores by holmium (Fig. 3.3b). 
 For enhancing their biocompatibility and in vivo stability, surface modification of the 
WI-MCNs was accomplished by PEGylation reactions; both covalent and non-covalent 
methods were evaluated. Non-covalent PEGylation with DSPE-PEG was selected because it 
could be accomplished quickly with minimum handing. The hydrophobic portion (DSPE) of 
this phospholipid PEGylating agent rapidly associated with the hydrophobic MCNs after 
sonication for 10 minutes. WI-MCNs-PEG were shown to increase in diameter by 
approximately 20 nm and the surface charge changed from neutral to a negative zeta potential 
(-24.9 mV) while retaining monodispersity (PDI = 0.126) (Fig. 3.2c). To assess if the non-
covalent PEG surface coating was stable following exposure to the neutron irradiation process, 
DSPE-PEGylated MCNs were irradiated in the nuclear reactor for 1, 5 and 10 hours. After a 1 
h irradiation, no sign of loss of surface coating was observed, and the MCNs were as readily 
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dispersed as they had been before neutron irradiation. However, when they were irradiated for 
5 and 10 h in the nuclear reactor with the same neutron flux, the DSPE-PEG coating was 
apparently not stable as the particles could no longer be dispersed in aqueous media (Fig. 3.7a). 
The size and PDI of MCNs were not altered even after 10 h of irradiation (Fig. 3.8). If longer 
periods of irradiation are required to produce greater amounts of 166Ho that result in desorption 
of the DSPE-PEG coating, then performing PEGylation after the neutron-activation process is 
a possibility because the non-covalent PEGylation reaction can be accomplished within 
minutes (Fig. 3.9). This strategy was shown to be effective for WI-MCNs that had been 
irradiated for 5 and 10 h (Fig. 3.7b). Post-irradiation PEGylation provides an added advantage 
in that it allows the attachment of protein or peptide ligands that target tumors to the surface of 
the PEGylated MCNs. 
 The cytotoxicity of MCNs was evaluated using a human ovarian cancer (A2780) cell 
line. The cells were exposed to three formulations (MCNs, WI-MCNs and DSPE-PEGylated 
WI-MCNs-PEG (WI-MCNs-PEG)), all containing the non-radioactive isotope of holmium 
(165Ho), for 48 h. As shown in Fig. 3.10a, none of these formulations induced any cytotoxicity 
at concentrations up to 100 g mL-1. Thus, any tumor-killing activity by neutron-activated 
carbon nanoparticles would be due to the radiation and not be the result of chemical toxicity of 
the nanoparticle. After confirming the safety of non-radioactive MCNs, the efficacy of 
radioactive WI-MCNs-PEG that had been irradiated in a neutron flux for one hour using a 
longer incubation time (72 h) with the A2780 cells. While the non-radioactive (165Ho) MCNs 
did not induce cytotoxicity after a 72 h incubation, the radioactive (166Ho) MCNs showed a 
clear tumor-killing effect at the 24 h time point which significantly increased after longer 
incubation times (48 h and 72 h) (Fig. 3.10b). It has been well established that larger absorbed 
radiation doses induce a greater tumoricidal effect [21-24]. 
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 The amount of 166Ho produced following irradiation of natural abundance holmium in 
a neutron flux was compared to the amount of other frequently employed therapeutic 
radionuclides (90Y and 177Lu) produced following neutron irradiation of yttrium and lutetium, 
respectively, under the same conditions.  (Fig. 3.11) [25]. While both 165Ho and 89Y have an 
isotopic natural abundance of 100%, 165Ho has much greater neutron capture cross-section than 
89Y (64 barns vs. 1.3 barns) and a shorter half-life (27 vs 64 h). While 176Lu has an 
approximately 40-fold larger neutron cross-section than 165Ho, its isotopic natural abundance 
is only 2.59% (Lu mostly exists as 175Lu in nature) and the half-life of 177Lu is also ~ 6-fold 
greater than 166Ho. Thus, the maximum amount of 166Ho that can be produced is much greater 
that the amount of 90Y and 177Lu, respectively, that can be produced when irradiating the same 
sample size under similar conditions.  
 
3.5 Conclusion 
 In summary, MCNs were investigated as a carrier material for neutron-activatable 
holmium for use in systemic radiation therapy. When compared to other nanoparticle systems 
that deliver therapeutic radionuclides, the neutron activation approach allows for easy 
production and adjustment of the radiation dose by using a neutron source with a different flux 
density (e.g., a higher power nuclear reactor), changing the time of irradiation, or increasing 
the loading of the stable isotope in the nanoparticle. MCNs were synthesized as spherical 
monodisperse particles with a diameter of approximately 150 nm. Their surface charge was 
neutral and they possessed a large surface area. A novel NMR method was employed for 
estimating the pore size distribution of the MCNs and revealed that these particles had an 
average pore size of 2.6 nm in diameter with a narrow pore size distribution. The wet 
impregnation loading method increased the loading capacity of the MCNs for holmium and 
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resulted in no leaching of 166Ho after irradiation for 10 h in a nuclear reactor. The surfaces of 
the MCNs were PEGylated in order to enhance their biocompatibility and to make them 
suitable for intravenous administration. A non-covalent PEGylation method was selected over 
a conventional covalent PEGylation approach because the latter requires oxidation of MCN 
surfaces with strong acids and multiple washing steps. This lengthy process would not be 
practical if it were applied to post-irradiation surface modification of the MCNs due to the 
relatively short half-life of 166Ho. Finally, in vitro cytotoxicity studies employing a human 
ovarian cancer cell demonstrated that the non-radioactive MCNs were themselves not toxic, 
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Figure 3.1 Theranostic application of mesoporous carbon nanoparticles (scheme produced 




Figure 3.2 Characterization of MCNs. a) SEM image of MCNs. b) The average particle size 
of MCNs and PEGylated MCNs by DLS. c) Pore size distribution of MCNs by NMR. 
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Figure 3.3 Change of physical characterization by WI a) N2 adsorption-desorption isotherm of 























Figure 3.6 In vitro leaching study of MCNs-Ho(AcAc)3-PEG and WI-MCNs-PEG.  
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Figure 3.7 Stability of DSPE-PEGylation after Neutron-Activation (a) Pre-Irradiation 
















Figure 3.10 In vitro cell viability with formulations in a human ovarian cancer cell line 
(A2780). (a) Cytotoxicity of MCNs, WI-MCNs (165Ho) and WI-MCNs-PEG (165Ho). (b) In 
vitro efficacy of radioactive WI-MCNs-PEG (208 µCi at 100 µg MCNs/mL) vs. non-
radioactive WI-MCNs-PEG. Groups were compared by two-way ANOVA (* for  p<0.05 and 
† for Bonferroni-adjusted pairwise p<0.05 from Concentrations of MCNs) and each 
concentration was analyzed by independent t-test (δ for adjusted p<0.05 from 166Ho-MCNs-
PEG (24 h), ε for adjusted p<0.05 from 166Ho-MCNs-PEG (48 h) and ϕ for adjusted p<0.05 
from 166Ho-MCNs-PEG (72 h)).  
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Figure 3.11 Calculated mCi of radionuclides produced following irradiation of 1 mg of natural 
abundance holmium, yttrium and lutetium in a thermal neutron flux of 5.5 x 1012 neutrons cm-
2 s as a function of time.  The dotted lines represent the maximum amount of the individual 
radionuclides that can be produced under these conditions (radionuclide decay after the end of 
irradiation is not displayed). The thermal neutron capture cross-sections and half-lives were 

































Table 3.1 Elemental analysis of MCNs and WI-MCNs by XPS. 
Element 
MCNs WI-MCNs 
Atomic % Weight % Atomic % Weight % 
C 94.2 92.4 79.2 61.9 
O 5.8 7.6 19.1 19.9 




















CHAPTER 4 NEUTRON-ACTIVATABLE NEEDLES FOR RADIONUCLIDE 
THERAPY OF SOLID TUMORS3 
 
4.1 Overview 
 Various approaches have been undertaken to enhance the delivery of therapeutic agents, 
including tissue-killing radionuclides, into solid tumors. Here we describe the preparation of 
Ti and Mo conical needles coated with Ho and Re by pulsed laser deposition or chemical vapor 
deposition. These needles can readily yield radioactive isotopes following irradiation in a 
neutron flux. The radioactive needles, whose design were based on solid microneedle arrays 
used in transdermal drug delivery, can be produced with minimal handling of radioactivity and 
subsequently inserted into tumors as a means of internal radiation therapy. Ho and Re, were 
specifically chosen because of their large neutron capture cross-sections as well as the desirable 
radiotherapeutic properties of the resultant radionuclides. Neutron-absorbing shields were also 
developed to prevent the production of unwanted radionuclides after neutron irradiation of the 
needle base materials. Neutron activation calculations showed that therapeutically significant 
amounts of radionuclides can be produced for treating solid tumors and stability studies 
demonstrated that Re did not leach off the Mo needles. These coated neutron-activatable 
needles offer a new approach to internal radiation therapy of tumors that allows precise 
tailoring of the absorbed radiation dose delivered to the tumor by controlling the coating 
thickness and the irradiation time. 
                                                 
3 Part of this chapter was submitted as an article to the Nulear Medicine and Biology as follows: 
J. Kim, R.J. Narayan, X. Lu, M. Jay “Neutron-Activatable Needles for Radionuclide Therapy 
of Solid Tumors.”, Journal of Biomedical Materials Research Part A (under review). 
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4.2 Introduction 
 The treatment of solid tumors, which continue to account for a significant number of 
deaths worldwide, remains a challenge. In order to deliver therapeutic agents to solid tumors, 
approaches that have been successfully used in the transdermal drug delivery field that do not 
involve simple passive diffusion have been investigated for intra-tumoral delivery of drugs, 
proteins and other therapeutics. These approaches include the use of focused ultrasound, 
iontophoresis and electroporation [1-3]. One approach that has not been previously explored is 
the use of microneedle technology. Microneedles have been fabricated in solid form to allow 
transport of therapeutics across the stratum corneum, in hollow form to allow delivery of drugs 
through a small orifice in the tip of the needle, and in a form composed of dissolvable materials 
that permit extended release of therapeutics. The focus of the current work is to fabricate a 
needle that would deliver therapeutic doses of radiation to tumors after penetration of the needle 
into solid tumors. This approach involves making the needle itself radioactive by coating them 
with elements that are readily activated to therapeutic radionuclides following irradiation in a 
neutron flux. Because the thickness of most solid tumors is much greater than the thickness of 
the stratum corneum (~15 m), our design involved needles of much greater length (300 µm - 
1 cm) than seen with most microneedle assemblies.  
 The use of therapeutic (particle-emitting) radionuclides to treat solid tumors remains as 
a prominent therapeutic option. Internal radiation therapy with sealed radioactive sources 
(brachytherapy) involves the delivery of high doses of targeted radiation with minimal off-
target effects by applying radioactive sources directly to or into the target tumors. 
Brachytherapy sources containing 192Ir or 103Pd are used in the treatment of prostate cancer, the 
second leading cause of cancer death in men in the United States, and cervical cancer, the 
second leading cause of cancer-related deaths in women in developing countries [4, 5]. In 
addition, ocular plaques containing 125I and 106Ru are used to treat tumors of the eye [6].  
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 Neutron-activation is an attractive method of generating radioactivity while minimizing 
radioactive exposure during handling. Holmium (Ho) is a promising neutron-activatable 
element as it is 100% naturally abundant (165Ho) and has a large neutron capture cross-section 
(59 barns; 1 barn = 10-24 cm2) [7]. After irradiation in a neutron flux, 166Ho is produced, which 
decays by the emission of high energy, tumor-killing β- particles (Emax = 1.86 MeV, half-life = 
26.8 h; maximum tissue penetration = 8.7 mm). This neutron-activation approach has been 
used to produce 166Ho-nanoparticles composed of mesoporous silica, mesoporous carbon and 
graphene oxide. This method demonstrated the generation of sufficient radioactivity to induce 
tumoricidal effect as not handling any radioactivity during the formulation preparation steps 
[8, 9].   
 Radiotherapeutic rhenium (Re) radioisotopes can also be produced by neutron 
activation of naturally abundant Re. It is a refractory metal with a very high melting point 
(3180 °C) and is resistant to wear and corrosion even at low pH and high salt condition [10-
12]. Among the refractory metals (niobium, molybdenum, tantalum and tungsten), Re element 
exhibits the greatest tensile and creep-rupture strength [10, 13]. In addition, Re does not form 
carbides, nor does it have a ductile-to-brittle transition temperature as it is ductile over a wide 
range of temperatures [12]. Thus, it has the capability to be utilized in various applications [11]. 
In nature, Re exists as two stable isotopes: 37.4% as 185Re (neutron capture cross-section = 112 
barns) and 62.6% as 187Re (neutron cross-section = 73 barns) [7]. As such, neutron-activation 
generates 186Re (Emax= 1.07 MeV, half-life = 89.2 h, maximum tissue penetration = 5 mm) and 
188Re (Emax = 2.12 MeV, half-life = 17.0 h, maximum tissue penetration = 11 mm) [14, 15]. 
The radioisotopes of Ho and Re produced by neutron activation also emit photons (-rays and 
x-rays). Any leaching of these elements from the microneedles after implantation in tumors 
can be monitored by obtaining images of their biodistribution using SPECT [14, 15]. Here we 
report on the production of custom-sized radiotherapeutic needles coated with neutron-
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activatable elements (Ho and Re) with the goal of minimizing the handling of radioactive 
material and improving internal radiation therapy (Fig. 1).  
 
4.3 Materials and Methods 
4.3.1 Chemicals 
 Holmium foil (1 mm thick, 99.9% trace rare earth metal basis), methanol (HPLC grade) 
and acetone (HPLC grade) were purchased from Sigma-Aldrich (St. Louis, MO). Phosphate 
buffered saline (PBS pH 7.4) was obtained from Fisher Chemical (Fair Lawn, NJ). Acetate 
buffer (USP heavy metal testing grade, pH 3.5) was acquired from Ricca Chemical (Arlington, 
TX). Holmium ICP-MS standard (pure single-element standard, 1,000 µg/mL in 2% HNO3) 
and rhenium ICP-MS standard (pure single-element standard, 1,000 µg/mL in 2% HNO3) were 
received from PerkinElmer (Waltham, MA). Gadolinium sputtering target (76.2 mm diameter, 
3.18 mm thick) was purchased from Alfa Aesar.  
 
4.3.2 Pulsed laser deposition (PLD) of Ho on Titanium (Ti) needles 
 Ti needles were prepared by the North Carolina State University (NCSU) precision 
instrument machine shop. Prior to deposition of Ho, needles were placed in an ultrasonic bath 
for 10 minutes in acetone and 10 minutes in methanol to remove impurities. Substrates were 
then placed in the PLD chamber. Ho foil was utilized as the PLD target. A KrF Lambda Physik 
LPX 200 excimer laser was operated at a wavelength of 248 nm and an output energy of 450 
mJ. A thin Ho film was deposited on the Ti needles using 10,000 shots, with a shot frequency 
of 20 Hz and a target frequency of 1 Hz. 
 
101 
4.3.3 Characterization of Ho-coated Ti needles 
 Scanning electron microscopy (SEM; Hitachi S-4700) was used for imaging of the 
micro-sized needles. Ho deposition was confirmed by energy-dispersive X-ray spectroscopy 
(EDS; Oxford instruments, INCA PentaFET). The thickness of Ho deposition was measured 
by atomic force microscopy (AFM, Asylum Research MFP3D Atomic Force Microscope). 
 
4.3.4 Chemical vapor deposition (CVD) of Re on molybdenum (Mo) needles. 
 Three Re coatings of varying thickness (25, 75 and 125 µm) were uniformly deposited 
on Mo needles by CVD. During this process, a precursor vapor containing rhenium 
pentachloride was passed over a heated needle substrate. CVD deposits were formed on the 
substrate at the molecular level, and the process achieved purity levels in excess of 99.99%. In 
addition, the CVD coating process exhibited the greatest throwing power, i.e., the ability to 
uniformly deposit materials onto/into intricately shaped or textured substrates. An essentially 
100% dense Re coating was deposited on Mo needles through the thermal decomposition of 
ReCl5 at 1100ºC.   
 
4.3.5 Gadolinium (Gd) neutron shield 
 A neutron shield made of pure Gd to prevent the formation of undesired Mo isotopes 
was produced by the NCSU precision instrument machine shop. The shield was designed to 





4.3.6 Stability assessment at different pH 
 Non-radioactive coated needles were incubated in 20 mL of PBS (pH 7.4) and in acetate 
buffer (pH 3.5) at 37 °C for up to 30 days. The leached amount of Ho and Re was quantified 
by inductively coupled plasma mass spectrometer (ICP-MS; Agilent 7500cx with Agilent 1260 
Infinity Bioinert LC). 
 
4.3.7 Leaching following by neutron-activation 
 Neutron-activatable radiation needles were irradiated for 10 minutes in the PULSTAR 
Reactor Facility at NCSU (reactor power = 1 MW; thermal neutron flux = 5.5 x 1012 neutrons 
cm-2 s). The irradiated samples were washed with 20 mL of Milli-Q water 3 times and the 
amount of radioactive Ho or Re in the washings was quantified with a γ-scintillation counter 
(PerkinElmer 2470 Wizard γ-counter). 
 
4.4 Results and Discussion 
 In order to tailor the amount of radioactivity produced by neutron activation of the 
needle, the total amount of Ho loaded onto the needle can be varied by the deposition process. 
PLD is a widely-adopted method of adhering thin films to a substrate [16]. With this method, 
when Ho foil was ablated in a vacuum with an intense pulsed laser, it was transformed into a 
plasma plume that condensed on the needle [17]. Among many candidates, Ti was selected as 
a base material because of its relatively low material cost, low density, high strength, good 
biocompatibility, resistance against corrosion and, most importantly, the low amount of 
radioactive Ti isotopes produced following neutron irradiation [18, 19]. Two prototypes with 
different needle sizes (300 µm and 1 cm) were manufactured, and Ho was deposited by PLD. 
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Needles with varying dimensions can be prepared and customized to the size of the tumor to 
be treated (Fig. 2a). Successful deposition of Ho on the needle was confirmed by elemental 
analysis using EDS and by morphological changes observed by SEM (Fig. 2b). The thickness 
of Ho coating was estimated to be 1.19 µm by AFM. Coating thickness can be easily modified 
by changing PLD parameters such the number of shots or shortening the frequency to achieve 
desired amount of metal loading. A thicker Ho coating on the Ti needles would reduce the 
irradiation time necessary to produce therapeutic quantities of radioactivity (166Ho). 
 A significant amount of heat is generated during the neutron activation process that 
could degrade the radiation delivery matrix leading to premature leaching of the radionuclide 
[20]. Therefore, it is important to assess how much radioactivity leaches from the matrix 
following neutron activation. In these studies, irradiation time was limited to 10 minutes in 
order to remain in compliance of our institution. The leaching studies showed that all of the Ho 
that had been deposited on the Ti needles by the PLD process remained on the needles 
following neutron irradiation and did not leach off when incubated and washed with water.  
 Since the neutron-activatable radiation needle was designed for use in solid tumors, a 
pH-stability study was conducted at physiological pH (7.4) as well as in a low pH environments 
that might be encountered with treating some solid tumors, e.g. cervical (pH  3.5) [21]. Ho 
deposition on the Ti needle was found to be stable at pH 7.4, but ultimately detached from the 
needle at pH 3.5. A change in color of the Ho coating, possibly due to oxidation, was also 
observed in acidic conditions. Thus, all subsequent efforts focused on the Re-coated Mo 
needles. 
 Mo is another refractory metal that is a reasonable choice for use as a needle base 
material due to its mechanical strength, resistance to corrosion, excellent machinability and 
biocompatibility [22]. We considered making entire needles of Re, but it is much more 
expensive than Mo and does not possess many of the desirable characteristic of Mo [12]. Mo-
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Re allows are often formed to offer protection against oxidation, wear and corrosion. Different 
compositions of Re-Mo alloys have been extensively investigated and employed for various  
applications, including biomedical, e.g., artificial heart valves [23, 24].  
 Based on the capacity for Mo to alloy favorably with Re, a needle was made of Mo and 
coated with Re by CVD. The size of this needle was 4 mm which was selected specifically for 
use in tumor-bearing mice models (Fig. 3a). Like PLD, CVD is often utilized for preparing 
elemental films via chemical deposition of a vapor-phase target onto a heated substrate [25]. 
Due to a faster and more homogenous deposition at a lower cost, CVD is generally considered 
to be more suitable for large-scale commercial production versus PLD. Based on these factors 
as well as from previous publications that reported success with CVD methods, the current 
study used CVD for Re deposition onto a Mo substrate (Fig. 3b,c) [12, 17]. Stability testing 
indicated that the Re coating stayed intact without leaching from the Mo needle even after 
incubation in different pH buffers for up to 30 days (Table 1). Only minimal leaching of 
radioactive Re was observed following neutron irradiation of the Re-coated Mo needles.  
 Although the Re-coated Mo needle was readily machinable, scalable and did not exhibit 
leaching of Re under diverse conditions, a new issue arose in terms of the production of 
undesirable radioisotopes of Mo following neutron irradiation. Compared to a Ti needle base, 
the Mo base generates a number of detectable isotopes, some of which are produced in 
substantial amounts (Table 2). 101Mo and 101Tc resulting from irradiation of Mo are produced 
in the greatest amounts, measuring 13.8 and 11.5 mCi, respectively, under simulated conditions 




 s). However, these isotopes decay quickly 
and concentrations becomes negligible within few hours due to their short half-lives (14.6 
minutes for 101Mo, 14.2 minutes for 101Tc). An additional isotope, 93Mo, can also be produced 
during the irradiation process. Neutron activation calculations revealed that non-negligible 
amounts (48.6 pCi) of 93Mo (t½  = 3500 y) could be produced under the standard irradiation 
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conditions. Although this amount of radioactivity is not very great, it must be taken into 
consideration when calculating radiation dosimetry for patients. The most noteworthy isotope 
resulting from Mo irradiation is 99mTc, which is a commonly used radionuclide in nuclear 
medicine for SPECT imaging. Contrary to previously discussed radioisotopes, the radioactivity 
of 99mTc increases with time from the decay of 99Mo until transient equilibrium is established 
(after ~24 h).  
 In order to avoid the production of these radioisotopes, a neutron shield was 
manufactured that would allow irradiation of the Re-coated needle, but not the Mo base. Gd 
was chosen as the shielding material because it has a very high neutron cross-section (49,700 
barns), and thus could shield the base of the needle by absorbing neutrons before they reach 
the base [26, 27]. As shown in Fig. 4, the Gd neutron shield was customized to the size of Mo 
needle and was comprised of two separate compartments (top and bottom) for easy separation 
following irradiation. Since the Gd shield itself will become radioactive following neutron-
activation, this facile shield removal method is desirable to minimize the handling time. 
Originally, only the needle itself was to be coated with the Re film, but during the process, 
some Re was unavoidably deposited on the base as well. (Fig. 3c). Therefore, the Gd shield 
was designed so that only the needle itself was exposed to neutrons.  
 Neutron-activation of Ho and Re was simulated and compared to yttrium (Y) (Fig. 5a), 
a therapeutic radionuclide used in commercial products (e.g., Zevalin® , TheraSphere® ) due to 
the energetic beta particles (βmax= 2.28 MeV) it emits [7, 28]. In spite of the 100% natural 
abundance of 89Y, its low neutron capture cross-section (1.28 barns) results in the production 
of small amounts of 90Y compared to 166Ho, 188Re and 186Re when neutron-activated under the 
same conditions. Although 185Re and 187Re both have larger neutron capture cross-sections than 
165Ho, the 100% natural abundance of 165Ho results in significantly larger amounts of 
radioactivity that can be produced. The difference between 166Ho and 188Re in the amount of 
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radioactivity that can be produced by neutron activation is not very different for irradiation 
times up to 20 h; longer irradiation times yield a greater amount of 166Ho that is produced.  
 Calculations were also performed to assess the time at which elements reached the 
maximum theoretical amount of radioactivity that could be produced under identical conditions 
(1 mg of natural abundance Ho, Re and Y irradiated in a thermal neutron flux of 5.5 x 1012 
neutrons cm-2 s). The properties of the stable and radioactive isotopes of these elements are 
shown in Table 3. Radionuclides with relatively short half-lives, such as 166Ho and 188Re, 
reached 90% of their maximum theoretical amount after 100 h of irradiation whereas 186Re and 
90Y reached only 54.0% and 66.1%, respectively. Fig. 5b depicts the amount of Ho, Re and Y 
radioisotopes produced under a protocol feasible for clinical utility, e.g., 10 h of neutron 
irradiation followed by a decay period of up to 2 days. It can be seen that similar amounts of 
166Ho and 188Re are available at the end of irradiation, but 188Re decays faster than 166Ho. 
Although a much smaller amount of 186Re is present at the end of irradiation, if a 48 h period 
is necessary to process and ship the neutron-activated needles, the amount 186Re would be 
essentially equal to the amount of 188Re after this time period due to the longer half-life of the 
former. 
 The amount of Re isotopes that can be produced from Re-coated Mo needles can be 
controlled by varying the amount of Re deposited on the needles. The different thicknesses of 
Re coating (25, 75, and 125 µm) correspond to depositions of 5.04, 15.6 and 26.9 mg of Re, 
respectively. Fig. 5c shows the calculated amounts of 186Re and 188Re produced after irradiation 
of needles coated with varying Re thickness for 10 h followed by an extended decay period.  
Interestingly, the 125 µm-coated 186Re needle was able to be produced more radioactivity for 




 The use of neutron-activated materials that can be inserted into tumors offers the 
possibility of customizing internal radiation therapy by selecting needle geometries, coating 
thicknesses and irradiation times for solid tumors of specific sizes and shapes. Ti and Mo were 
selected as base materials for the needles because of their machinability, while Ho and Re were 
selected as the neutron-activatable materials to be coated on the needles because of their 
favorable nuclear properties (high neutron capture cross-sections, isotopic natural abundance, 
half-lives and decay properties of the resultant radionuclides). The ultimate dose of radiation 
produced by neutron activation of Ho or Re can be also easily controlled either by varying the 
thickness of the Ho/Re coating or selecting an appropriate neutron-irradiation time. The 
stability of the coatings, which was accomplished using PLD for Ho deposition on Ti needles 
and CVD for Re deposition on Mo needles, was assessed following irradiation in a nuclear 
reactor and incubation in solutions of varying pH, including those anticipated at tumor sites. 
The irradiation of the Ti base material produces very small amounts of short-lived Ti 
radioisotopes. However, when Mo is used as the base material, Mo radioisotopes and daughters 
(99mTc) can be produced by neutron activation. Thus, a neutron absorbing shield comprised of 
Gd was used during the irradiation of the Re-coated Mo needle to minimize the production of 
non-rhenium radioisotopes that could complicate the calculation of absorbed radiation does to 
the tumors and non-target other tissues. The implementation of a neutron-activatable needles 
would create new opportunities for tailoring the internal radiation of solid tumors. The next 
generation of this technology will involve the use of true microneedles that can deliver soluble 
radionuclides into tumor cells in a manner that transdermal microneedles deliver drugs across 
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Figure 4.1 Illustration of neutron-activatable coated needles for internal radiation therapy.  
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Figure 4.2 Ho deposition on Ti needles by PLD. a) Ho-coated Ti needles: 300 µm (left) and 1 
cm (right). b) SEM image of 300 µm Ti needle showing surface morphology before and after 
Ho deposition.  
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Figure 4.3 Mo needle coated with Re by CVD. a) Mo needle b) Re-coated Mo needle (25 µm 








Figure 4.4 Gd neutron shield for Re-coated Mo needle. a) Schematic design of Gd neutron 
shield. b) Customized two-compartment Gd neutron shield (top and bottom). c) Re-coated Mo 





Figure 4.5 Calculated amounts of radioactivity produced in a thermal neutron flux of 5.5 x 
1012 neutrons cm-2 s as a function of irradiation time [7]. (a) Irradiation of 1 mg of natural 
abundance Ho, Re and Y (the dotted lines denote the maximum theoretical amount of the 
individual radionuclides that can be produced under these conditions). (b) The amount of Ho, 
Re and Y radioisotopes produced by a 10 h neutron irradiation followed by a 48 h decay. (c) 
The amount of Re radioisotopes produced by a 10 h neutron irradiation of Re-coated needles 
















Table 4.1 Leaching of Re and Mo from Re-coated Mo needles when incubated in buffers of 
different pH values, and after neutron irradiation and three 20 mL washing with Milli-Q water.  
Testing Condition Mo leaching (%) Re leaching (%) 
Acetate Buffer (pH 3.5) 
Day 1 0.006 0.001 
Day 2 0.006 0.000 
Day 3 0.007 0.000 
Day 30 0.133 0.001 
PBS (pH 7.4) 
Day 1 0.032 0.001 
Day 2 0.029 0.001 
Day 3 0.031 0.000 
Day 30 0.627 0.002 
Neutron Irradiation 
Wash 1 - 0.109 
Wash 2 - 0.009 













Table 4.2 Calculation of radioactivity generated by irradiation of 900 mg of natural abundance 




 s and allowing for decay for up 
to 240 hours after the end of irradiation [7]. 
  Radioactivity after x h Delay 
Radionuclides Half-life 0 h  10 h 24 h 168 h 240 h 
93
Mo 3500 y 48.6 pCi 48.6 pCi 48.6 pCi 48.6 pCi 48.6 pCi 
99
Mo 65.9 h 264 µCi 237 µCi 205 µCi 45.1 µCi 21.2 µCi 
99m
Tc 6.01 h 12.8 µCi 152 µCi 182 µCi 43.5 µCi 20.4 µCi 
101
Mo 14.6 m 13.8 mCi 6.09E-15 Ci 0 0 0 
101















Table 4.3 Properties of stable neutron-activatable nuclides and resultant radionuclides 











165Ho 100 59 166Ho 26.8 
187Re 62.6 73 188Re 17.0 
185Re 37.4 112 186Re 89.2 















CHAPTER 5 SUMMARY AND FUTURE DIRECTIONS 
 In this dissertation, carbon nanomaterials and custom-sized needles were investigated 
as material matrices for the purpose of producing therapeutic radionuclides by neutron-
activation. To examine radiation therapies practiced in the clinic, various types were reviewed 
and a neutron-activation strategy was chosen for development of some applications. Parameters 
involved in neutron-activation and several candidates for neutron-activatable radionuclides 
were also discussed to determine the ideal option to be loaded or coated on material matrices. 
Following a thorough selection process, holmium (Ho) was chosen for its 100% natural 
abundance, therapeutically applicable energy level, proper radioactive t1/2 and capability of 
theragnostic application with SPECT imaging [1]. 
 The use of nanocarriers was required for neutron-activatable radionuclides to target 
various cancers via the passive tumor-targeting effect [2]. Carbon-based nanocarriers were 
hypothesized to be an ideal candidate for this application due to desirable characteristics such 
as rigid structure, high metal loading capacity, low density, heat-resistance and ability to 
withstand the harsh environment during the neutron-activation process. Subsequent to 
reviewing carbon nanomaterials in biomedical applications, two different carbon nanocarriers 
- graphene oxide nanoplatelets (GONs) and mesoporous carbon nanoparticles (MCNs) - were 
selected as potential Ho delivery carriers. 
 GONs were successfully synthesized from a graphite and characterized by analytical 
techniques. By non-covalent PEGylation, their dispersity and Ho-loading capacity were 
significantly enhanced. Also, they did not leach Ho under 1 h of neutron-irradiation and 
condition mimicking physiological stress. On the other hand, they were able to steadily release 
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radioactive Ho in an in vitro model of the tumor microenvironment, which is expected to be 
beneficial for enhanced tumor penetration. Cytotoxicity evaluation of GONs with non-
radioactive Ho confirmed their biocompatibility. In future studies, in vivo efficacy and 
pharmacokinetics of the formulation will be assessed in a tumor-bearing animal model. 
Moreover, Ho will be adhered to GONs via employing chelators, which will prevent the release 
of Ho in a mildly acidic condition, and they will be used as the control for demonstrating the 
advantage of selective Ho release from GONs. GONs will also be explored for the platform 
technology with other radionuclides which can offer varying merits.         
 In spite of the superior properties of GONs, there was some difficulty to produce GONs 
of uniform size and shape (critical factors in clinical translation) since large sized GONs were 
broken down to a nano-scale by strong mechanical energy. To compensate for these 
shortcomings, MCNs was synthesized from a phenol formaldehyde resin by a soft-template 
method. Their physical characteristics – morphology, size, pore size, and elemental 
composition – were assessed with imaging and analytical methods. In addition, surface 
modification on MCNs conferred dispersibility and biocompatibility. One of the main 
objectives of this project was achieving the complete prevention of Ho leaching. Therefore, 
holmium oxide particles were physically entrapped inside of MCNs by synthesis within the 
pores, and this resulted in complete prevention of holmium leaching even after prolonged 
irradiation period (10 h). In vitro cell-based assays confirmed that the inactive MCN-based 
formulation was not toxic and the same formulation following a 1 h irradiation demonstrated a 
sufficient tumoricidal effect. 
  The MCN formulation will be validated for efficacy with in vivo cancer models. For 
systemic radiation therapy application, xenograft tumor model with an ovarian cancer cell line 
was already developed. Upon intravenous injection of 166Ho-incorporated MCNs to tumor-
bearing mice, tumor shrinkage and survival will be evaluated in contrast to the non-radioactive 
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control. Furthermore, this formulation will be explored for brachytherapy application with an 
orthotopic glioblastoma (GBM) mouse model [3]. After removing the GBM by surgery, 166Ho-
MCNs will be directly placed in the resection cavity and survival function of this formulation 
will be analyzed. As discussed in Chapter 3, post-irradiation PEGylation is available for MCNs, 
which creates an opportunity to attach biological targeting ligands (peptides or proteins). By 
conjugating targeting ligands to the end of a PEG chain, an active targeting approach on MCNs 
can be pursed in the future.  
 A combination therapy of neutron-activatable radionuclide carriers with 
radiosensitizing chemotherapeutics is anticipated to maximize the therapeutic outcomes; 
GONs and MCNs have proven to be excellent chemo-drug carriers with a superb loading 
capacity [4, 5]. However, determining the stability of candidate chemotherapeutics in a nuclear 
reactor is prerequisite for the chemoradiation therapy.  
 The last application of neutron-activation technology was developing a radiation needle 
for solid tumors. To replace large-sized radiation applicators in current use, custom-sized 
needles were manufactured with titanium (Ti) and molybdenum (Mo). In the first generation 
of the needle, Ho was deposited to a Ti needle by pulsed laser deposition (PLD); however, Ho 
was leached under acidic environment by oxidation. Thus, a new version of the needle was 
prepared with another neutron-activatable radionuclide, rhenium (Re). Since Re-Mo alloys 
have been utilized for protection purposes against oxidation, wear and corrosion, Re was coated 
on a Mo needle by chemical vapor deposition (CVD) [6]. Though this needle improved upon 
the leaching issues of the first generation, undesirable radioisotopes of Mo were produced by 
neutron irradiation. A gadolinium (Gd) neutron shield was designed and customized to the size 
of the Mo needle as a solution of preventing Mo irradiation. In the future study, radioactive 
Re-coated Mo needles will be inserted in the xenograft tumor model to assess Re leaching 
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under in vivo condition. A successful in vivo stability test will lead the needle subsequent 
assessment of in vivo efficacy. 
 In conclusion, the successful outcome of these projects conducted in this dissertation is 
expected to yield a new paradigm for more convenient and less invasive treatment of cancer 
patients, potentially increasing not only objective outcomes of response rates and survival, but 
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